

Drew Moghanaki, MD, MPH, FASTRO

Professor of Radiation Oncology
Chief of Thoracic Oncology | UCLA Department of Radiation Oncology
Stanley Iezman and Nancy Stark Endowed Chair in Thoracic Radiation Oncology Research
David Geffen School of Medicine at UCLA; UCLA Jonsson Comprehensive Cancer Center
Staff Physician & Co-Director VA Greater Los Angeles Lung Precision Oncology Program

PERSONAL CONTACT:

Email: dmoghanaki@mednet.ucla.edu

Telephone: 804-306-9045

EDUCATION

1988-94 BS, Biochemistry - California Polytechnic State University
1994-97 MPH, Epidemiology - University of California, Los Angeles
2000-22 MD, Vanderbilt University Medical School
Texas Tech U Health Sciences Center School of Medicine (1997-99)
UC San Diego, Howard Hughes Medical Institute Fellowship (1999)
2002-03 General Surgery Internship - Vanderbilt University Medical Center
2003-08 Radiation Oncology Residency - University of Pennsylvania

LICENSURE

2002-03 Tennessee Medical License (Training)
2003-05 Delaware Medical License
2003-08 Pennsylvania Medical License (Training)
2004-08 Pennsylvania Medical License
2008-20 Virginia Medical License
2010-11 Tennessee Medical License
2019-21 Georgia Medical License
2021- California Medical License

BOARD CERTIFICATION

June 2009 American Board of Radiology, Radiation Oncology

PROFESSIONAL EXPERIENCE

| | |
|------------------------|---|
| July 2008 – May 2015 | Assistant Professor of Radiation Oncology Virginia Commonwealth University |
| July 2008 - April 2011 | Medical Director VCU Massey Cancer Center Southside Regional Medical Center Petersburg, Virginia |
| May 2011 – Jan 2019 | Staff Physician Radiation Oncology Service Hunter Holmes McGuire VA Medical Center Richmond, Virginia |
| May 2011 – Jan 2019 | Director, Brachytherapy Services Radiation Oncology Service Hunter Holmes McGuire VA Medical Center Richmond, Virginia |
| May 2011 – Jan 2019 | Director. Clinical Radiation Oncology Research Radiation Oncology Service Hunter Holmes McGuire VA Medical Center Richmond, Virginia |
| May 2015 – Jan 2019 | Associate Professor of Radiation Oncology Virginia Commonwealth University |
| Jan 2019 – Feb 2021 | Associate Professor of Radiation Oncology Emory University School of Medicine |
| Jan 2019 – Feb 2021 | Chief, Radiation Oncology Atlanta VA Health Care System |
| Mar 2021 - | Professor, Chief of Thoracic Oncology Department of Radiation Oncology David Geffen School of Medicine at UCLA |
| Mar 2021 - | Staff Physician VA Greater Los Angeles Healthcare System |
| July 2021 - | Co-Director, Lung Precision Oncology Program VA Greater Los Angeles Healthcare System |
| Mar 2026- | Professor, Physics and Biology and Medicine Department of Radiation Oncology David Geffen School of Medicine at UCLA |

PROFESSIONAL ACTIVITIES

Clinical Service Contributions

1. Southside Regional Medical Center, Petersburg, VA, 2008-11
 - Established tumor board for hospital
 - Chaired the hospital's ethics committee
 - Established seminar series in oncology for community providers
 - Established new IMRT program for head and neck cancer
2. VCU Massey Cancer Center / Medical College of Virginia, 2008-19
 - Established a clinic offering affordable radiation therapy to increase access to care for patients enrolled in hospice
3. Hunter Holmes McGuire VA Medical Center, 2011-19
 - Founded the VA National Palliative Radiotherapy Taskforce
 - Established national center of excellence for prostate brachytherapy
 - Introduced pancreas SBRT program
 - Introduced liver SBRT program
 - Introduced prostate cancer hydrogel program
 - Introduced MRI-guided targeted prostate biopsy program
 - Introduced MRI-guided prostate cancer active surveillance program
4. Atlanta VA Health Care System
 - Introduced lung SBRT program
 - Introduced spine SBRT program
 - Introduced prostate SBRT program
 - Introduced prostate cancer fiducial and hydrogel program
5. VA Greater Los Angeles Healthcare System
 - Introduced single-fraction lung SBRT program
6. UCLA Health
 - Optimized lung SBRT workflows, introducing single-fraction SBRT
 - Developed MR-guided lung SBRT program
 - Introduced gated lung SBRT program

Grants and Protocol Reviewer: Institutional

1. Protocol Reviewer - VCU Massey Cancer Center, Protocol Research Monitoring Committee, 2011-18

Grants and Protocol Reviewer: National

1. Chair - Association of Veterans Affairs Hematology/Oncology Scholarship, 2016-21
2. Reviewer - LUNGeity Career Development Award Study Section, 2019-
3. Reviewer – LUNGeity VA Career Development Award Study Section, 2022-
4. Reviewer - DOD CDMRP, Lung Cancer Research Program (LCRP), 2020-22
5. Reviewer - ASTRO-LUNGeity Residents/Fellows Scholarship, 2022-24
6. DSMB Member - "Improving Decision-Making Encounters in Lung Cancer (iDECIDE): A Low-Literacy Conversation Tool", PI: Donald Sullivan, Oregon Health Sciences University, Sponsor VA CSRD, 2023-2027
7. Grants Reviewer – VA Office of Research and Development Health Systems Research, 2024
8. Concept Review Panel Member - VA Lung Precision Oncology Program, 2025

Grants and Protocol Reviewer: International

1. Cancer Research UK, 2016
2. Netherlands Organisation for Health Research and Development, 2022
3. Canadian Cancer Clinical Trials Network, 2023
4. Dutch Cancer Society, 2025
5. Netherlands Organisation for Health Research and Development, 2025

Committee Membership: International

1. Scientific Committee – Turkish Society for Radiation Oncology, International Advanced Radiotherapy Techniques Symposium, 2025

Committee Membership: National

1. Member - American Cancer Society Breast Cancer Prevention Campaign, Petersburg, VA, 2008–11
2. Founder / Former Chair / Member - VHA National Palliative Radiotherapy Taskforce, 2012–19
3. Member – VHA National Radiation Oncology Program Field Advisory Committee, 2012–16
4. Member - Society of Palliative Radiation Oncology, 2014–19
5. Member - ASTRO Palliative Care Working Group, 2014–15
6. Board Member at Large - Association of Veterans Affairs Hematology/Oncology 2014–18
7. Chair - Association of VA Hematology/Oncology Research Committee, 2015–present
8. Member - ASTRO Evidence Based Guideline Taskforce: Stereotactic Body Radiotherapy for Early-Stage Non-Small Cell Lung Cancer, 2015-17
9. Member - ASCO Practice Guidelines Implementation Network, 2016–Present
10. Board Member - Lung Cancer Alliance, Medical and Professional Advisory Board, 2016–2019
11. Co-Chair - ASTRO Genitourinary Scientific Committee, 2012–15
12. Chair - ASTRO Genitourinary Scientific Committee, 2016–19
13. Board Member - Lungevity Foundation Scientific Advisory Board, 2017–
14. Member – American Cancer Society, National Lung Cancer Round Table - Screening Implementation Strategies Task Group, 2017-
15. Steering Committee – ACR, Lung Cancer Screening 2.0 Committee, 2018-
16. Member – ACR Radiology, Veterans Affairs Committee, 2018-
17. Scientific Leadership Board - GO2 Foundation for Lung Cancer, 2019-2024
18. Member – ASTRO Radiation Oncology Institute Development Committee, 2019-21
19. Member – ASCO Thoracic Guidelines Advisory Group, 2020-2024
20. Subject Matter Expert – Veterans Health Administration, National Lung Cancer Screening Tool, Integrated Project Team, 2020-2021
21. Member – SWOG VA Working Group, 2021-
22. Board Examiner – American Board of Radiology, Thoracic Cancer and Sarcoma Category, 2022-2023
23. Member – NRG Oncology Lung Committee, 2022-2025
24. Steering Committee – American Cancer Society National Lung Cancer Round Table, 2024-2027
25. Global Advisory Council – GO2 Foundation for Lung Cancer, 2025-2027

26. Scientific Advisory Board – Lung Cancer Foundation of America, 2025-

Committee Membership: Institutional

1. Director - Tumor Board, Southside Regional Med Ctr, Petersburg, VA, 2008-10
2. Chair - Ethics Committee, Southside Regional Med Ctr, Petersburg, VA, 2009–11
3. Chair - Cancer Committee, Southside Regional Med Ctr, Petersburg, VA, 2009-11
4. Associate Member - VCU Massey Cancer Center, Radiation Biology and Oncology Program, 2008–16
5. Member - Resident Research Committee - VCU Department of Radiation Oncology, 2009–17
6. Member - Admissions Committee, VCU School of Medicine, 2007-16
7. Member - Multidisciplinary Oncology Care Committee, VCU Massey Cancer Center, 2012–13
8. Member - Protocol Review & Monitoring Committee, VCU Massey Cancer Center 2012–18
9. Member - Thoracic Working Group, Winship Cancer Institute at Emory University School of Medicine, 2019-21
10. Faculty Search Committee - UCLA Department of Radiation Oncology 2019-
11. Chair Search Committee - Thoracic Surgery, UCLA Department of Surgery 2022
12. Member - Associate Chief of Staff for Research Search Committee, VA Greater Los Angeles, 2022
13. Chair - Faculty Promotions Committee, UCLA Department of Radiation Oncology, 2022
14. Executive Member - Lung Cancer Committee, UCLA Health Jonsson Comprehensive Cancer Center
15. Vice-Chair - Academic Physician Search Committee, UCLA Department of Radiation Oncology, 2022
16. Protocol Reviewer – Disease Site Group Review Committee, UCLA Jonsson Cancer Center, 2023
17. Chair Review Committee – Dean’s Office, David Geffen School of Medicine at UCLA, 2023-2025
18. Chair Search Committee – Head and Neck Surgery, David Geffen School of Medicine at UCLA, 2025

Committee Membership: International

1. Member – IASLC, Patient Advocate Committee, 2019-26

Scientific Conference Organizer: Administrative

1. Co-Chair – ASTRO GU Scientific Committee, 2014
2. Co-Chair – ASTRO GU Scientific Committee, 2015
3. Planning Committee, American Brachytherapy Society GU Scientific Track, 2016
4. Co-Chair – ASTRO GU Scientific Committee, 2016
5. Chair – ASTRO GU Scientific Committee, 2017
6. Conference Chair – VA Partnership to Increase Access to Lung Cancer Summit, 2018
7. Chair – ASTRO GU Scientific Committee, 2018
8. Chair – ASTRO GU Scientific Committee, 2019
9. Meeting Program Committee, RSS Annual Scientific Meeting, 2019

10. Conference Chair – VA Partnership to Increase Access to Lung Cancer Summit, 2020
11. Meeting Program Committee – RSS Annual Scientific Meeting, 2020
12. Meeting Program Committee – RSS Annual Scientific Meeting, 2023
13. Meeting Program Committee – RSS Annual Scientific Meeting, 2024
14. Meeting Program Committee – RSS Annual Scientific Meeting, 2025
15. Meeting Program Committee – American Cancer Society National Roundtable Annual Meeting, 2025
16. Scientific Committee – International symposium on Advanced Radiotherapy Techniques (iARTIST), 2026
17. Co-Chair – IASLC World Conference on Lung Cancer, Global Health, Health Services, and Health Economics Track, 2026

Scientific Conference Moderator

1. ASTRO Annual Scientific Meeting GU Oral Presentation Session, 2012
2. ASTRO Annual Scientific Meeting GU Oral Presentation Session, 2015
3. ASTRO Annual Scientific Meeting GU Oral Presentation Session, 2017
4. ASTRO Annual Scientific Meeting GU Oral Presentation Session, 2018
5. Radiosurgery Society Annual Meeting “Lung SABR/SBRT: Current Challenges and Future Directions”, 2019
6. ASTRO Annual Scientific Meeting, “Recruitment to Difficult Randomized Clinical Trials: Lessons from PARTiQoL, VALOR, and ProtecT”, 2019
7. AVAHO Annual Meeting, “Clinical Trial Updates from VA Central Office”, 2020
8. AVAHO Annual Meeting, “How to Successfully Lead Clinical Trials in the VA”, 2020
9. Atlanta Lung Cancer Symposium, Plenary Session, Lung Cancer Symposium, 2020
10. ASCO Advantage Course: Non-Small Cell Lung Cancer, 2021
11. AVAHO Annual Meeting, “Research Networks in the Veterans Health Administration”, 2021
12. GO2 Foundation Centers of Excellence Virtual Summit, “VA Lung Precision Oncology Program”, 2021
13. IASLC World Conference on Lung Cancer, “Stories of Success: Equity, Stigma and Campaigning for Change”, Session Chair, 2026

Conference Abstracts Reviewer

1. ASTRO 2011, GU Section, Annual Meeting
2. ASTRO 2012, GU Section, Annual Meeting
3. ASTRO 2013, GU Section, Annual Meeting
4. ASTRO 2014, GU Section, Annual Meeting
5. ASTRO 2015, GU Section, Annual Meeting
6. ABS, 2016, GU Section, Annual Meeting
7. ASTRO 2016, GU Section, Annual Meeting
8. ASTRO 2017, GU Section, Annual Meeting
9. ASTRO 2018, GU Section, Annual Meeting
10. ASTRO 2019, GU Section, Annual Meeting
11. RSS 2020, Annual Scientific Meeting
12. WCLC 2021, Early Stage/Localized Disease/Ablative Therapies Track
13. RSS 2023, Annual Scientific Meeting
14. RSS 2024, Annual Scientific Meeting

15. RSS 2025, Annual Scientific Meeting
16. WCLC 2025, Global Health, Health Services, and Health Economics Track
17. WCLC 2025, Global Health, Health Services, and Health Economics Track

Supervisory Teaching

Academic Faculty Mentorship and Advising

1. Joshua Meeks, MD, PhD – Assistant Professor of Urology and Biochemistry and Molecular Genetics, Feinberg School of Medicine at Northwestern University, 2016-2019
2. Abhishek Solanki, MD - Assistant Professor of Radiation Oncology, Loyola University, 2019-
3. William Stokes, MD - Assistant Professor of Radiation Oncology, Emory University School of Medicine, 2020-
4. Reid Thompson, MD, PhD – Assistant Professor of Radiation Oncology, Oregon Health Sciences University, 2017-2020
5. Jennifer Lewis, MD, MPH - Assistant Professor of Medicine, Hematology/Oncology, Vanderbilt University, 2020-2024
6. Millie Das, MD – Associate Professor of Medicine, Oncology, Stanford University, 2021-2024
7. Lucas Vitzthum, MD – Assistant Professor of Radiation Oncology, Stanford University, 2021-2024
8. Diana Gage, MD, PhD – Associate Professor of Radiation Oncology, UCLA, 2021-
9. Lawrence Benjamin, MD, PhD – Assistant Professor of Pulmonary, Critical Care & Sleep Medicine, 2022-2025

Residency Program Mentorship - beyond routine rotating trainees

1. Alfredo Urdaneta, MD – VCU, Resident 2009-11
2. Jeremy Karlin, MD – VCU, Resident 2010-15
3. Jessica Schuster, MD – VCU, Resident 2011-14
4. Matthew Schutzer, MD – VCU, Resident 2012-14
5. James Taylor, MD – Thomas Jefferson, Resident 2019-20
6. Yusef Syed, MD - Emory, Resident 2020-21
7. David Qian, MD - Emory, Resident 2020-21
8. Aviva Berkowitz, MD - Albert Einstein College of Medicine, Resident 2021
9. Luca Valle, MD - UCLA, Resident 2021-22
10. Clayton Smith, MD – UCLA, Resident 2021-22
11. Alex Bryant, MD, MS – University of Michigan, Resident 2021-23
12. Travis Courtney, MD – UCLA, Resident 2022-25
13. John Nikitas, MD – UCLA, Resident 2022-25
14. Haley Tupper, MD – UCLA, Surgery Resident, 2023-

Medical Students

1. Brett Adams, Medical College of Virginia, 2012-13
2. David Asher, Medical College of Virginia, 2013-15
3. Shannon Nesbitt, DGSOM at UCLA, 2024-25

Graduate Students

1. John Charters, Thesis Review Committee UCLA, 2024
2. Claudia Miller, Thesis Review Committee UCLA, 2026

Undergraduate Students

1. Matthew Williams, Johns Hopkins University, 2014-15
2. Emily Harris, University of Virginia, 2014-15
3. Emily Wang, UCLA, 2024-25

Journal Editorial Boards

1. Editorial Board – Prostate Cancer and Prostatic Diseases, 2014–21
2. Associate Editor – JNCI Cancer Spectrum, 2025-
3. Editorial Board – Scientific Reports, 2026-

Journal Reviewer

1. Practical Radiation Oncology, 2011
2. Journal of Urology, 2012
3. Prostate Cancer and Prostatic Diseases, 2012
4. Prostate Cancer, 2012
5. Journal of Pain and Symptom Management, 2012
6. Journal of Palliative Medicine, 2012
7. IJROBP, 2012
8. British Journal of Urology International, 2013
9. Annals of Palliative Medicine, 2015
10. Radiotherapy & Oncology, 2015
11. Cancer Medicine, 2015
12. Federal Practitioner, 2016
13. Brachytherapy, 2016
14. Scandinavian Journal of Urology, 2016
15. American Journal of Clinical Oncology, 2016
16. Annals of the American Thoracic Society, 2016
17. JAMA Oncology, 2017
18. Lung Cancer, 2017
19. Clinical Lung Cancer, 2018
20. Advances in Radiation Oncology, 2018
21. JCO Clinical Cancer Informatics, 2018
22. PLOS ONE, 2020
23. BMC Cancer, 2021
24. CHEST, 2021
25. Contemporary Clinical Trials Communications, 2022
26. AIMS Medical Science, 2022
27. JCO Oncology Practice, 2022
28. New England Journal of Medicine, 2023
29. Journal of Thoracic and Cardiovascular Surgery, 2023
30. Cancer, 2023

31. Thoracic Cancer, 2024
32. Journal of Clinical Oncology, 2024
33. Journal of Thoracic Oncology, 2024
34. BMJ Oncology, 2025
35. European Journal of Surgical Oncology, 2025
36. Journal of Thoracic Oncology Clinical Research Reports, 2025

Government Service

1. Civilian Staff Physician – Hunter Holmes McGuire Veterans Affairs Medical Center, 2011-19
2. Member - Veterans Health Administration National Radiation Oncology Program Field Advisory Committee, 2012–16
3. Civilian Staff Physician – Atlanta VA Health Care System, 2019-20
4. Subject Matter Expert – Veterans Health Administration, National Lung Cancer Screening Tool, Integrated Project Team, 2020-2021
5. Civilian Staff Physician – West Los Angeles VA Medical Center, 2020-
6. Advisor – VA Cooperative Studies Program Epidemiology Analytics Resource (CSPEAR), Office of Research and Development, 2021-
7. External Advisory Board – VA Integrated Network 7 Lung Precision Oncology Program, 2021-22
8. Co-Chair – VA Lung Precision Oncology Program Biomarker Sub-Workgroup, 2021-curr
9. Operational Partner – VA Evidence Synthesis Program “Non-surgical Therapies for Early-stage Non-small Cell Lung Cancer”, 2022-2023
10. Field Research Advisory Committee - Department of Veterans Affairs Office of Research and Development, 2025-2028

Scientific Consulting

1. Scientific Adjudication Committee Member, LOCATE Clinical Trial [NCT02680041] - Blue Earth Diagnostics, 2017-2018
2. Advisory Board – Janssen Pharmaceuticals, 2018
3. Consultant – AstraZeneca, 2020-23
4. Advisory Board – Accuray, 2021
5. Scientific Advisory Board – LungLife AI, 2021-curr
6. Consultant – Delfi Diagnostics, 2022-23
7. Consultant – ViewRay, 2022-23
8. Consultant – Auratera, 2025-curr
9. Consultant – Oatmeal Health, 2025-curr
10. Consultant – Open Medicine, 2025-curr

RESEARCH GRANTS AND FELLOWSHIPS RECEIVED

Active Federal

| | |
|----------------|---|
| Grant Title | Randomized Trial of Mobile Application to Improve Health-Related Outcomes in Patients with Advanced Lung Cancer |
| Funding Agency | DOD - Defense Research and Engineering (LC230562): |
| Role | Co-Investigator (PI: Temel) |

Dates 2024-27
Total Costs \$650,000

Grant Title Bringing 4π radiation therapy to the clinic
Funding Agency NIH SBIR Phase IIB, R44CA183390-05
Role Co-Investigator and PI of Clinical Trial, 10% Effort (PI: Sheng)
Dates 2022-2026
Total Costs \$4,000,000

Grant Title Greater Los Angeles VA Lung Precision Oncology Program
Funding Agency VA Cooperative Studies Program
Role Co-Principal Investigator, 25% Effort (co-PI: Dubinett)
Dates 2021-26
Total Costs \$4,519,170

Grant Title Veterans Affairs Lung Cancer Surgery or Stereotactic
Radiotherapy Phase III Randomized Clinical Trial (CSP #2005)
Funding Agency VA Cooperative Studies Program
Role Co-Chair, 50% Effort
Dates 2013–29
Total Costs \$41,383,931

Active Private

Grant Title Re-Evaluating Lung Cancer Screening Eligibility Criteria
Funding Agency Bristol Myers Squibb Foundation
Role Principal Investigator, 10% Effort
Dates 2024-25
Total Costs \$118,761

Grant Title California Partnership to Increase Access to Lung Screening
Funding Agency Bristol Myers Squibb Foundation
Role Principal Investigator, 10% Effort
Dates 2024-27
Total Costs \$2,500,550

Grant Title CT-Guided LDR Brachytherapy for Adenoid Cystic Carcinoma
Lung Metastases: Efficacy and Safety Outcomes
Funding Agency Adenoid Cystic Carcinoma Research Foundation
Role PI, 1% Effort
Dates June 2024 – December 2024
Total Costs \$50,000

Grant Title CT-Guided LDR Brachytherapy for Adenoid Cystic Carcinoma
Lung Metastases: Efficacy and Safety Outcomes
Funding Agency Theragenics Corporation
Role PI, 1% Effort
Dates April 2024 – April 2026
Total Costs \$50,400

Grant Title The Role of SGLT2 Inhibition on Lung Cancer Incidence and Clinical Outcomes
 Funding Agency UCLA Jonsson Comprehensive Cancer Center and Jonsson Cancer Center Foundation
 Role PI, 1% Effort
 Dates April 2024 – May 2025
 Total Costs \$139,680

Previous Support

Grant Title Fellowship for High School Teachers
 Funding Agency National Institutes of Health
 Role Fellow
 Dates Summer 1997
 Total Costs \$5,000

Grant Title Medical Student Research Fellowship
 Funding Agency Howard Hughes Medical Institute
 Role Fellow
 Dates 1999-2000
 Total Costs \$26,000

Grant Title Educational Video Research Study
 Funding Agency VCU Massey Cancer Center
 Role Co-Investigator, 5% Effort (PI: Matsuyama)
 Dates 2011-2012
 Total Costs \$30,000

Grant Title LC180227 - “Targeting ART1, a Novel Immune Checkpoint, for the Treatment of Lung Cancer”
 Funding Agency Department of Defense, Office of the Congressionally Directed Medical Research Programs (CDMRP)
 Role Co-Investigator, 3% (PI: Stiles)
 Dates January 2019-2021
 Total Costs \$350,000
 Site Costs \$60,950

Grant Title Implementing CRISPR/Cas9 Genomic Screens to Identify Genetic Risk Factors for Lung Radiation Injury
 Funding Agency Department of Defense, Office of the Congressionally Directed Medical Research Programs (CDMRP)
 Role Co-Investigator, 1% Effort (PI: Pfister)
 Dates October 2020-2021
 Total Costs \$312,000

Grant Title VA Partnership to Increase Access to Lung Screening
 Funding Agency Bristol-Myers Squibb Foundation
 Role PI, 25% Effort
 Dates July 2017– June 2022
 Total Costs \$7,029,581

| | |
|----------------|--|
| Grant Title | VA Partnership to Increase Access to Lung Screening (VA-PALS) |
| Funding Agency | VA Office of Rural Health, Enterprise-Wide Initiative |
| Role | PI, 25% Effort |
| Dates | July 2017 – September 2022 |
| Total Costs | \$2,632,775 |
| | |
| Grant Title | Program Evaluation of VA-Partnership to Increase Access to Lung Screening (VA-PALS) |
| Funding Agency | VA Office of Rural Health |
| Role | Co-Investigator, 2% Effort (co-PI: Lewis and Spalluto) |
| Dates | November 2018 – September 2022 |
| Total Costs | \$317,803 |
| | |
| Grant Title | Morningside-VA-Winship Cancer Analytics Program |
| Funding Agency | Woodruff Health Sciences Center Foundation |
| Role | PI, 2% Effort |
| Dates | August 2019 – March 2023 |
| Total Costs | \$217,951 |
| | |
| Grant Title | Measuring Provider Engagement in Lung Cancer Screening |
| Funding Agency | LUNgevity Foundation |
| Role | Co-Investigator, 2% Effort (co-PI: Lewis and Spalluto) |
| Dates | 2021-23 |
| Total Costs | \$100,000 |
| | |
| Grant Title | The Boston University – UCLA Lung Cancer Biomarker Characterization Center, BDL |
| Funding Agency | NIH/prime; Boston University/PTE |
| Role | Co-Investigator, 8% effort (PI: Dubinett) |
| Dates | 2022-23 |
| Total Costs | \$22,046 |
| | |
| Grant Title | Program Vision Leader Award: Understanding Barriers to Lung Cancer Screening in an Academic Healthcare System |
| Funding Agency | UCLA Jonsson Cancer Center Foundation |
| Role | PI, 1% |
| Dates | May 2022 – May 2024 |
| Total Costs | \$50,000 |
| | |
| Grant Title | Phase 2 Randomized Clinical Trial Comparing the Safety and Efficacy of PULSAR-Integrated Radiotherapy + Pembrolizumab or Nivolumab Administered with or Without STING-Agonist IMSA101 in Patients with Oligoprogressive Solid Tumor Malignancies (Protocol# IMSA101-103) |
| Funding Agency | Immune Sensor LLC |
| Role | Site PI, 1% Effort |
| Dates | 2023-24 |
| Total Costs | \$64,610 |

LECTURES AND PRESENTATIONS

Invited Lectures - Institutional

1. Invited Lecturer – “Non-Traditional Pathways to Medical School”, **University of Pennsylvania Post-Baccalaureate Program**, 2006
2. Grand Round Lecture - “A Boy Named Africa”, **Children’s Hospital of Philadelphia**, 2007
3. Grand Rounds Lecture - “Adjuvant Therapy following Resection of Pancreatic Cancers - 25 Year Experience at the Hospital of the University of Pennsylvania”, **University of Pennsylvania Abramson Cancer Center**, 2008
4. Invited Lecture - “Prostate Cancer: Fundamentals of Treatment”, **VCU Radiation Therapy Training Program**, 2009
5. Speaker - “Technological Advances in Radiation Oncology” – **VCU Massey Cancer Center Alliance Development Group**, 2009
6. Invited Lecture – “The Utility, Perils, and Myths of Radiation for Head & Neck Cancers”, **VCU Dept of Otolaryngology**, 2010
7. Invited Lecture - “Palliation of Cancer Related Symptoms with Radiotherapy”, **VCU Department of Palliative Medicine**, 2011
8. Grand Rounds Lecture - “The Value of Integrating Radiation Oncology Earlier in the Multi-Disciplinary Process”, Hematology Oncology and Palliative Care, **VCU Massey Cancer Center**, 2011
9. Grand Rounds Lecture - "Stereotactic Radiotherapy for Early-Stage Lung Cancer - A Potential Alternative to Surgery", **Hunter Holmes McGuire VA Medical Center**, 2013
10. Invited Lecture - “The Role of a Radiation Oncologist in Prostate Cancer”, **VCU Department of Medical Oncology**, 2013
11. Invited Lecture - “When to Radiate and When to Not”, **2nd Annual VCU Palliative Care Symposium**, 2013
12. Grand Rounds Lecture - “Multiparametric MRI-based Active Surveillance for Prostate Cancer: An Alternative to Discontinuation of PSA Screening”, **Hunter Holmes McGuire VA Medical Center**, 2014
13. Invited Lecture - "Can Stereotactic Radiotherapy Eliminate the Need for Lung Cancer Surgery?", **VCU School of Medicine Microbiology & Immunology**, 2016
14. Grand Rounds Lecture - “Beyond Screening: Stereotactic Radiotherapy as an Alternative to Surgical Resection for Operable Stage I Lung Cancer”, **Hunter Holmes McGuire VA Medical Center**, 2016
15. Invited Lecture - “Medical Management of Radiation Oncology Patients”, **VCU School of Allied Health, Department of Radiation Sciences**, 2016
16. Invited Lecture - “The Importance of Teamwork between Physicians and Therapists”, **VCU Radiation Therapy Training Program**, 2017
17. Invited Lecture - “Update on Local Treatment Options for High-risk Prostate Cancer”, VCU Massey – **Community Memorial Hospital Cancer Symposium**, Sept 2017
18. Invited Lecture - “Non-surgical Management of Pancreas & Liver Cancers: The Role of Stereotactic Radiotherapy”. **VCU Massey – Community Memorial Hospital Cancer Symposium**, September 2017
19. Invited Lecture - “Stereotactic Radiotherapy for Screen Detected Lung Cancer”, **VCU School of Medicine Radiation Oncology Interest Group**, March 2018
20. Invited Lecture - “Teamwork in the Radonc Clinic”, **VCU Radiation Therapy Training Program**, July 2018

21. Grand Rounds Lecturer – “Lung Cancer Screening Made Safe and Simple”, **Department of Medicine, David Geffen School of Medicine at UCLA**, 2021
22. Invited Lecture – “Management of Locally Advanced NSCLC”, **VA Greater Los Angeles Pulmonary Thoracic Oncology Multidisciplinary Conference**, June 2023
23. Invited Lecture – “Understanding Barriers to Lung Cancer Screening in an Academic Healthcare System”, **UCLA Jonsson Comprehensive Cancer Center Symposium**, May 2024
24. Invited Panelist – “Cancer Screening Lessons from Different Healthcare Organizations”, **Healthy Lungs California: Engaging Providers & Health Systems on Lung Cancer Screening**, **David Geffen School of Medicine at UCLA**, November 2024
25. Invited Speaker – “Environmental Exposures and Lung Cancer Risk”, **Wildfire & Cancer Symposium, UCLA Health Jonsson Comprehensive Cancer Center**, April 2025
26. Invited Lecture – “Misunderstood Post-Radiotherapy Scars”, **VA Greater Los Angeles Pulmonary Thoracic Oncology Multidisciplinary Conference**, May 2025
27. Invited Lecture – “Thoracic Radiation Oncology 101”, **UCLA Division of Pulmonary, Critical Care & Sleep Medicine**, Oct 2025
28. Grand Rounds Lecture – “Lung Cancer Screening: Simpler Than You Think”, **Department of Medicine, David Geffen School of Medicine at UCLA**, Dec 2025
29. Invited Lecture – “Radiation Pneumonitis or Parenchymal Scarring?”, **VA Greater Los Angeles Pulmonary Thoracic Oncology Multidisciplinary Conference**, June 2026

Invited Lectures and Visiting Professorships - National

1. Visiting Professor Lecture - “How are Radiation Oncologists Currently Managing Patients with Biochemical Progression following Prostatectomy?”, Department of Radiation Oncology, **University of Virginia**, 2011
2. Visiting Professor - “Optimizing Post-Prostatectomy Salvage Radiotherapy”, Department of Radiation Oncology, **University of Washington**, 2012
3. Invited Lecture - “Modern Advances in Radiotherapy for Elderly Cancer Patients: Extending, while Improving Quality of Life”, 24th **Annual Virginia Geriatrics Society Conference**, 2013
4. Invited Speaker - “Radiation Oncologists’ Opportunities with Prostate mpMRI, Targeted Biopsies, and Active Surveillance”, Department of Radiation Oncology, **Johns Hopkins Medical Institute**, 2014
5. Invited Speaker - “High Risk Prostate Cancer: Radiotherapy versus Surgery Debate”, **ACRO Annual Meeting**, Washington DC, 2014
6. Invited Speaker - “Stereotactic Ablative Radiotherapy for Stage I Lung Cancer: A Potentially Curative Alternative to Surgery”, **American College of Osteopathic Internists Annual Convention**, Baltimore, October 2014
7. Invited Speaker - “Behind the Curtains of Cancer Research”, American Studies Program, **College of William & Mary**, 2015
8. Visiting Professorship Lecture - “History, Trends, and Opportunities for Radiation Oncology Research in the Veteran’s Healthcare Administration”, Department of Radiation Oncology, **University of Pennsylvania**, 2015

9. Webinar Lecturer - "Stereotactic Radiotherapy for Operable Stage I Non-Small Cell Lung Cancer: A New Generation of Randomized Trials", **The Radiosurgery Society**, 2016
10. Grand Rounds Lecture - Is Surgery Still the Optimal Treatment for Stage I Non-Small Cell Lung Cancer? The VALOR Trial", **Georgia Regents University Cancer Center**, 2016
11. Invited Speaker - "State of the Art Management of Locally Advanced Unresectable Pancreatic Cancer The Role of SBRT", **Augusta University** GI Symposium, 2016
12. Invited Speaker - "Is Surgery Still the Optimal Treatment for Stage I Non-Small Cell Lung Cancer? The VALOR Trial", **Radiosurgery Society Annual Meeting**, Orlando, 2016
13. Invited Speaker - "Randomized Trials for Patients with Operable Stage I NSCLC", **VA Portland Healthcare System**, 2016
14. Invited Speaker - "Behind the Curtains of Cancer Research", American Studies Program, **College of William & Mary**, 2016
15. Grand Rounds - "Establishing the Standard of Care for Operable Stage I NSCLC with Clinical Trials", **VA Boston Medical Center Department of General Surgery**, 2016
16. Invited Speaker - "Safe Implementation of SBRT: Planning and Delivery", **Veterans Health Administration** Advanced Radiation Therapy Technologies & Treatment Training Conference, Boston, 2016
17. Visiting Professor - "Difficult Randomized Trials", **The James Cancer Center**, Ohio State University, January 2017
18. Visiting Professor - "Difficult Randomized Trials in Oncology", Department of Radiation Oncology, **Henry Ford Health System**, April 2017
19. Invited Lecture - "The VALOR Lunar Module: A Phase III Trial for Operable Stage I NSCLC", **American Thoracic Society: NIH Symposium on Moonshot**, Washington, DC, May 2017
20. Invited Speaker - "VA Partnership to Increase Access to Lung Cancer Screening Implementation Network", **Initiative for Early Lung Cancer Research on Treatment Conference**, Mt Sinai Hospital, NY, June 2017
21. Visiting Professor - "Difficult Randomized Trials in Oncology", Department of Radiation Oncology, Department of Radiation Oncology, **Emory University**, September 2017
22. Keynote Speaker - "Implementation of New Technologies to Improve Efficiency and Quality of Patient Care: Automating Clinical Workflow", MIM Software Users Meeting at **ASTRO Annual Meeting**, San Diego, September 2017
23. Visiting Professor - "Stereotactic Radiotherapy for Screen Detected Veterans with Lung Cancer", **University of Miami**, Department of Radiation Oncology, Miami, November 2017
24. Educational Session Leader - "Optimizing Post-Prostatectomy Radiotherapy: A Multi-Disciplinary Perspective", **ASTRO Annual Meeting**, San Diego, September 2017
25. Invited Lecture - "Recruiting Patients to a Randomized Trial of Surgery vs Radiotherapy", **Roudebush VA Medical Center**, Indianapolis, December 2017
26. Invited Speaker - "Stereotactic Radiotherapy for Screen Detected Veterans with Lung Cancer", **David Geffen School of Medicine at UCLA**, Department of Radiation Oncology, Los Angeles, December 2017
27. Invited Speaker - "The Pervasiveness of Misguided Beliefs Among Physicians", American Studies Program, **College of William & Mary**, 2017
28. Visiting Professorship - "Difficult Randomized Trials", Department of Radiation Oncology, **University of Virginia**, 2017

29. Invited Speaker - "Genitourinary Presentations", **Best of ASTRO**, Miami, November 2017
30. Invited Speaker - "SBRT Lung Plan Study", **The Radiosurgery Society Annual Scientific Meeting**, Las Vegas, November 2017
31. Webinar Lecturer - "SBRT Lung Plan Study", **The Radiosurgery Society**, December 2017
32. Invited Speaker - "Surgery, SBRT, and the Uninformed Preferences of Patients with Operable Stage I NSCLC", **MD Anderson Thoracic Oncology Multidisciplinary Research Conference**, Houston, January 2018
33. Keynote Speaker - "Stereotactic Radiotherapy for Screen Detected Lung Cancer", **Philadelphia Roentgen Ray Society**, March 2018
34. Invited Speaker - "EduCase Lung SBRT eContouring Symposium", **American Radium Society Annual Meeting**, Orlando, May 2018
35. Invited Speaker - "VA Partnership to Increase Access to Lung Screening", **International Early Lung Cancer Action Program 38th Conference**, New York, March 2018
36. American Radium Society Annual Meeting, Orlando, May 2018
37. Invited Speaker - "Expanding our Intellectual Horizons on Twitter", **American Brachytherapy Society Annual Meeting**, San Francisco, June 2018
38. Invited Speaker - "Phase III Veterans Affairs Lung Cancer Surgery or Stereotactic Radiotherapy Trial VALOR", **NRG Oncology Lung Cancer Committee**, Philadelphia, July 2018
39. Invited Speaker - "VA Partnership to Increase Access to Lung Screening", **Veterans Health Administration National Radiology Conference**, Orlando, September 2018
40. Invited Speaker - "Genitourinary Highlights", **ASTRO Annual Meeting**, San Antonio, October 2018
41. Invited Speaker - "Stereotactic Radiotherapy for Screen Detected Stage I NSCLC", **30th Annual Fall Foliage Cancer Conference**, Asheville, October 2018
42. Invited Speaker - "VA Partnership to Increase Access to Lung Screening", **American Cancer Society National Lung Cancer Roundtable**, Crystal City, October 2018
43. Invited Speaker - "Update on VALOR and VAPALS", **39th International Conference on Screening for Lung Cancer and 8th Conference on Research for Early Lung Cancer Treatment**, Hyde Park, NY, October 2018
44. Invited Speaker - Residency Leadership Development Retreat, **Cleveland Clinic**, December 2018
45. Grand Rounds Lecture - "Increasing Access to Lung Cancer Screening for Veterans", **Vanderbilt-Ingram Cancer Center and VA Tennessee Valley Healthcare System Primary Care Lecture Series**, 2019
46. Invited Speaker - "Stereotactic Radiotherapy for Hepatocellular Carcinoma" 7th Annual **Veterans Affairs HCC Summit**, Miami, March 2019
47. Session Leader - "Lung SABR/SBRT Workshop: Current Challenges and Future Directions", **The Radiosurgery Society Annual Scientific Meeting**, San Diego, March 2019
48. Invited Speaker - "Lung Screening in the VA", **40th International Conference on Screening for Lung Cancer**, New York, April 2019
49. Grand Rounds Lecture - "Clear Obstacles and Hidden Challenges with Recruitment to Difficult Randomized Trials", **Georgetown Lombardi Comprehensive Cancer Center**, May 2019
50. Invited Speaker - "Best of ASTRO GU", **American Brachytherapy Society Summit**, Big Sky, MT, 2020

51. Invited Speaker – “Update on VA Partnership to Increase Access to Lung Cancer”, **Veterans Health Administration National Office for Specialty Care Services**, Washington DC, June 2020
52. Invited Speaker – Virtual Education Program – “Radiation for Oligometastatic Lung Cancer: Slippery Slope or New Frontier?”, **ASCO Annual Meeting** (Virtual), June 2020
53. Webinar Lecturer - “Navigating Tumor Board Discussions as a Radiosurgeon” **The Radiosurgery Society**, Feb 2021
54. Grand Rounds Lecture & Visiting Professor- **Northwell Health Cancer Institute, Zucker School of Medicine at Hofstra** (Virtual) May 2021
55. Invited Speaker – “Increasing Access to Lung Cancer Screening through the VA Lung Precision Oncology Program”, **American Thoracic Society Annual Meeting** (Virtual), May 2021
56. Invited Speaker – “Clinical Trial Updates in Lung Cancer Screening”, Perspectives in Lung Cancer Care, **Medscape Oncology** Webinar, August 2021
57. Webinar Speaker – “Understanding the Role of SBRT in Ultracentral Lung Tumors”, **The Radiosurgery Society** November 2021
58. Invited Panelist – “Lung SBRT Planning Rounds”, **The Radiosurgery Society** Webinar, January 2022
59. Invited Speaker - 14th **Cleveland Clinic Annual International Symposium on Stereotactic Body Radiation Therapy and Stereotactic Radiosurgery**, Orlando, February 2022
60. Keynote Speaker – 3rd Annual Conquering Veteran Cancer Together “Mitigating Racial Disparities for Veterans with Cancer through Equal Access Healthcare”, **ASCO Annual Meeting**, Chicago, June 2022
61. Invited Speaker – “VA Cooperative Studies Program Network of Dedicated Enrollment Sites”, **VHA National Radiation Oncology Program**, (Virtual), July 2022
62. Invited Speaker – **VHA National Radiation Oncology Program** Biennial Meeting, October 2022
63. Invited Panelist – “Thoracic Tumor Board”, **Society for Advanced Body Imaging Annual Meeting**, New Orleans, October 2022
64. Visiting Professor (virtual) – “SBRT for Early Stage Operable Stage I NSCLC”, **Department of Radiation Oncology, Thomas Jefferson University**, November 2022
65. Invited Panelist (virtual) – “Early-Stage Lung Cancer: Case-Based Teaching Sessions with Faculty” **Radiation Oncology Virtual Education Rotation (ROVER)**, December 2022
66. Invited Panelist – “Late Breaking Updates in Thoracic Oncology - What's Coming”, **American Association for Thoracic Surgery 103rd Annual Meeting**, Los Angeles, May 2023
67. Invited Speaker – “CSP #2005: A Phase III Randomized Trial of Lung Cancer Surgery or Stereotactic Radiotherapy for Operable Early-Stage Non-Small Cell Lung Cancer (VALOR)”, **VA Research Week, Milwaukee VA Medical Center**, May 2023
68. Invited Speaker – “Lung SBRT”, **Association for Bronchology and Interventional Pulmonology** - Fellowship Core Conference Series, June 2023
69. Invited Speaker – “Impact of MISSION Act on Lung Cancer Care”, **VA National Lung Cancer Precision Oncology Program**, June 2023
70. Invited Speaker – “The Art of Recruitment to Difficult Randomized Clinical Trials”, **ROCKET Research Meeting, Medical College of Wisconsin**, December 2023
71. Invited Speaker – “Management of Locally Advanced Non-Small Cell Lung Cancer”, **14th Annual Pacific Coast Lung Health Conference**, Los Angeles, December 2023

72. Keynote Speaker – “Has Radiation Therapy Replaced Surgery for Early-Stage NSCLC?”, **3rd Global Summit on Thoracic Malignancies**, Waimea, Hawaii June 2024
73. Invited Speaker – “Shedding Light on the VA Precision Oncology Platform and the Importance of Data-Driven Studies over Models”, **3rd Global Summit on Thoracic Malignancies**, Waimea, June 2024
74. Invited Speaker – “Fostering a Culture of Compassion and Support for People with Lung Cancer”, **American Cancer Society National Lung Cancer Round Table Annual Meeting**, Atlanta, December 2024
75. Invited Speaker – “Lung Cancer: Clinical Trials Meet Clinical Practice”, **61st Annual Meeting of The Society of Thoracic Surgeons**, Los Angeles, January 2025
76. Grand Rounds Lecture – “Shifting Lung Cancer Outcomes in the Veteran Healthcare Administration”, **Massachusetts General Brigham Cancer Center**, Boston, January 2025
77. Invited Speaker – “Distinguishing Immune-Related vs Radiation Pneumonitis following Thoracic Radiotherapy”, **American College of Radiology**, Webinar, February 2025
78. Keynote Speaker – “Building Institutional Alignment and Support”, **BMSF Grantee Summit**, Denver, April 2025
79. Invited Speaker – “VALOR Trial”, **48th International Conference on Screening for Lung Cancer & the 16th Conference on Early Lung Cancer Research on Treatment**, New York, October 2025
80. Invited Speaker – “Driving Innovation in Precision Oncology to FORESEE and Transform Lung Cancer Outcomes” **Advancing Lung Cancer Research for Veterans, National Association of Veterans' Research and Education Foundations**, Washington DC, November 2025
81. Invited Speaker – “Updating the USPSTF Guidelines”, **ALCI Innovative Challenge Webinar**, January 2026
82. Visiting Professor – **Northwell Health System, Department of Radiation Medicine**, New York, March 2026
83. Invited Moderator - "When to Consider SBRT vs. Surgery in Surgically Fit Patients?" AATS Online Institute Lung Cancer Series, Webinar, March 2026
84. Visiting Professor – **Mayo Clinic Department of Radiation Medicine**, Rochester, July 2026

Invited Lectures and Visiting Professorships - International

1. Grand Rounds – “SBRT for Low-Risk Operable Stage I NSCLC: The Veterans Affairs Phase III VALOR Trial”, University of Lausanne Cancer Center, **Switzerland**, 2016
2. Invited Lecturer – “Stereotactic Radiotherapy for Operable Stage I NSCLC”, Ain Shams Clinical Oncology Conference, Cairo, **Egypt**, November 2016
3. Visiting Professor – Department of Radiation Oncology, Hospital University Bern, **Switzerland**, May 2017
4. Invited Lecturer – “Upfront SBRT for Operable Stage I NSCLC”, 36th International Conference on Screening for Lung Cancer, Zurich, **Switzerland**, May 2017
5. Invited Lecturer - “Stereotactic Radiotherapy and Snake Oil”, Canadian Cancer Lung Conference, Vancouver, **Canada**, February 2018
6. Invited Discussant – “Lung SBRT Presentations”, IASLC World Conference on Lung Cancer, Toronto, **Canada**, September 2018

7. Keynote Speaker - "Complexities and Solutions for Randomized Trials of Surgery versus SABR for Stage I NSCLC", UK SABR Consortium, Bristol, **England**, November 2018
8. Invited Lecturer – "Type of lung resections in NSCLC Solid < 2cm - When I Favor Radiotherapy", 5th Annual Immersion Course in Minimally Invasive Thoracic Surgery, Quebec City, **Canada**, July 2019
9. Keynote Speaker - "The Uninformed Preferences of Patients with Operable Stage I NSCLC", Royal Australian and New Zealand College of Radiologists Annual Scientific Meeting, Auckland, **New Zealand**, October 2019
10. Invited Lecturer – "Utilizing SBRT to Improve Patient Selection for Surgical Resection of Stage I NSCLC", Mexican National Congress of Oncology, Mexican Society of Oncology, (Virtual) **Mexico**, October 2020
11. Invited Lecturer – "Practical aspects of radiation therapy for the patient with NSCLC treated with a radical (curative) intent", Mexican Society of Radiation Oncology, (Virtual) **Mexico**, August 2021
12. Invited Lecturer – "Technological innovation in Thoracic Radiotherapy of Lung Cancer", 8th Ain Shams University International Clinical Oncology Conference, (Virtual), Cairo, **Egypt** September 2021
13. Invited Lecturer – "Lung Cancer Screening – Who Should Be Screened?" and "Should SBRT in Early Lung Cancer be indicated only for inoperable patients?", III Semana Brasileira Da Oncologia, (Virtual) **Brazil**, November 2021
14. Invited Lecturer – "Contemporary Management of Lung Cancer: Hope to Reality" Tata Memorial Cancer Center; XX Annual Conference on Evidence Based Management of Cancers in India, (Virtual), Mumbai, **India**, February 2022
15. Invited Lecturer – "Contemporary Update in Thoracic Radiation Oncology", New Zealand Lung Cancer Conference, Auckland, **New Zealand**, June 2022
16. Invited Lecturer – "Managing Specialty Bias for Stage III NSCLC", Royal Australian and New Zealand College of Radiologists, Adelaide, **Australia**, October 2022
17. Grand Rounds Lecture – "Contemporary Roles of Radiation Therapy for Lung Cancer", Prince of Wales Hospital, Sydney, **Australia**, November 2022
18. Invited Lecturer – "Real World Evidence with Durvalumab", Monash Hospital, Melbourne, **Australia**, November 2022
19. Visiting Professor – "Multidisciplinary Lung Cancer Care", Peter MacCallum Cancer Center, Melbourne, **Australia**, November 2022
20. Invited Lecturer – "The UCLA Experience with MR guided SBRT for Lung, Pancreas and Prostate Cancer", UK SABR Consortium, Sheffield, **England**, November 2022
21. Invited Lecturer – "The Importance of Genomic Tests for Radiation Oncologists in NSCLC." Turkish Radiation Oncology (TROD) Online Meeting. **Turkey**, Sept 2023
22. Invited Lecturer – "Converting unresectable to resectable in NSCLC: are we ready?" AstraZeneca Lung Summit, Madrid, **Spain**, October 2023
23. Invited Lecturer – "US Lung Cancer Screening: how the US experience could help the development of screening in LMIC & what is the role of the radio-oncologist", 6 Congresso Internacional De Radioterapia Barretos, Barretos, **Brazil**, May 2024
24. Invited Lecturer - 2nd Annual Early Stage Lung International eXpert Retreat (ELIXR), Montreal, **Canada**, June 2024
25. Invited Lecturer – "Might Radiation Therapy Replace Surgery for Early-Stage NSCLC?", **European** School of Oncology (Virtual), September 2024 <https://www.eso.net/sessions/3974>
26. Grand Rounds Lecture – "Proper Management of Resectable Stage III NSCLC in the Era of Immunotherapy", American Association for Thoracic Surgery Global Webinar, **Global** (Virtual), September 2024

27. Invited Lecture – “Building a Brighter Future for Cancer Care through Partnerships with Patient Advocates”, BC Cancer Virtual Academic Forum, **Canada**, Feb 2025
28. Invited Lecturer – “Life after VALOR: How to Consider the Possibilities”, SABR Canada Conference, Kelowna, **Canada** June 2025
29. Invited Lecture - "Current evidence and development of adaptive radiotherapy in thoracic tumors, Summer School of Clinical Adaptive Radiotherapy, Negrar di Valpolicella, **Italy**, June 2025
30. Invited Lecture – “Radiotherapy for the Management of Lung Cancer: Advances, Inequalities, and Prospects”, Mexican Society of Radiation Oncology National Webinar, **Mexico**, August 2025
31. Invited Lecture – “Expanding the Role of Radiation Therapy”, World Conference on Lung Cancer, Barcelona, **Spain**, September 2025
32. Keynote Speaker, “Impact of SABR on Lung Cancer Screening”, Peter Mac SABR Symposium, Melbourne, **Australia**, November 2025
33. Invited Lecturer, “Fighting for cure in localized disease”, Lung Cancer Fight Club, Champalimaud Foundation, Lisbon, **Portugal**, March 2026
34. Keynote Speaker, “The Public Image of Radiation Oncology”, Sociedades Latino Americanas de Radioterapia, Santiago, **Chile**, April 2026
35. Keynote Speaker, “Missing the Target: Radiation, “Toxicity”, and Public Fear”. Congreso Sociedad Chilena de Radioterapia Oncologica, Huilo Huilo, **Chile**, April 2026
36. Invited Lecture, “Locally Advanced Lung Cancer in the Immunotherapy Era: What Future for Concurrent Chemoradiation”, Congreso Sociedad Chilena de Radioterapia Oncologica, Huilo Huilo, **Chile**, April 2026
37. Invited Lecture, “SBRT vs Surgery in Early-Stage Lung Cancer” Congreso Sociedad Chilena de Radioterapia Oncologica, Huilo Huilo, **Chile**, April 2026
38. Invited Lecturer, “Using Lung SBRT to Bridget the Gap: Access, Efficiency, and Equity in Radiation Oncology”, Saudi Association of Radiation Oncology, Webinar, **Saudi Arabia**, May 2026
39. Visiting Professor, “Non-Surgical Treatment of Stage III NSCLC”, Royal Adelaide Hospital, Dept of Radiation Oncology, **Australia**, May 2026
40. Invited Lecture, “Lung SBRT Updates”, International Stereotactic Radiosurgery Society (ISRS 2026) Congress, **Australia**, May 2026
41. Invited Lecture, “Navigating Social Media for Doctors”, International Stereotactic Radiosurgery Society (ISRS 2026) Congress, **Australia**, May 2026
42. Invited Lecture, “Non-Surgical Treatments for Operable Lung Cancer”, International Stereotactic Radiosurgery Society (ISRS 2026) Congress, **Australia**, May 2026
43. Invited Lecturer, “MR Guided Lung SBRT for The Most Challenging Tumors”, Spanish Society of Radiation Therapy Oncology, Alicante, **Spain**, June 2026
44. Keynote Speaker, “Public Fear and Toxicity”, International symposium on Advanced Radiotherapy Techniques (iARTIST), Istanbul, **Turkiye**, June 2026
45. Invited Discussant, “Pushing the Boundaries: Innovative Strategies in Unresectable Non-Small Cell Lung Cancer”, World Conference on Lung Cancer, **South Korea**, September 2026
46. Invited Speaker, “Non-Surgical Treatments for Early Stage Non-Small Cell Lung Cancer”, International Society of Stereotactic Radiosurgery, **Global Webinar**, November 2026

Community Outreach Lectures

1. Speaker - "Breast Cancer Screening and Treatment, What's New?" – Senior Circle Group, **Southside Regional Medical Center**, Petersburg, VA, 2008
2. Speaker - "Prostate Cancer: What you need to know" – Dinner with a Doc Program, **Southside Regional Medical Center**, Petersburg, VA, 2008
3. Invited Lecture - "Review of GI Malignancies", CME Lecture, **Southside Regional Medical Center**, Petersburg, 2008
4. Invited Lecture - "Technological Advances in Modern Radiation Oncology", CME Lecture, **Southern Virginia Regional Medical Center**, Emporia, 2009
5. Invited Lecture - "Review of GI Malignancies", CME Lecture, **Southside Regional Medical Center**, Petersburg, 2008
6. Speaker - "Colon Cancer" – Healthy Woman Health Education Program – **Southside Regional Medical Center, Petersburg**, VA, 2009
7. Speaker - "Breast and Cervix Cancer" – Healthy Woman Health Education Program – **Southside Regional Medical Center**, Petersburg, VA, 2009
8. Speaker - "Identifying Cancer When It's Still Curable" – **American Cancer Society**, Brunswick County, VA, 2009
9. Speaker - "Oncology" – Richmond Boy Scouts Troop #829 – Midlothian, VA, 2009
10. Invited Lecture - "Technological Advances in Modern Radiation Oncology", CME Lecture, **Southside Regional Medical Center**, Petersburg, 2009
11. Speaker - "Lung Cancer" Healthy Woman Health Education Program – **Southside Regional Medical Center**, Petersburg, VA, 2009
12. Speaker - "Breast Cancer" - **Gilfield Baptist Church**, Petersburg, VA, 2009
13. Speaker - "History of breast cancer treatment" – **Susan G. Komen Event for Faith-Based Leaders**, Petersburg, VA, 2009
14. Speaker - "Taking control of your health – it may save your life" – **Metropolitan Baptist Church**, Petersburg, VA, 2010
15. Speaker - "Colon and Prostate Cancer" – Laypersons educational series – **Appomattox Health and Wellness Center**, Petersburg, VA, 2010
16. Speaker - "Radiation in Medicine" – **Robious Middle School**, Midlothian, VA, 2010
17. Speaker - "Modern Treatments for Cancer" – Dinner with a Doc Series, **Southside Regional Medical Center**, Petersburg, VA, 2010
18. Speaker - "We Are All Captains of Our Ship" – American Cancer Society Relay for Life, **Southside Virginia Community College**, 2011
19. Invited Lecture - "High Breast Cancer Mortality in the Tri-Cities", CME Lecture, **Southside Regional Medical Center**, Petersburg, 2011
20. Speaker - "What you need to know about cancer now that you're over 50" – **Veterans of Foreign Wars**, Petersburg, VA, 2012
21. Speaker - "Compassionate Radiotherapy Program for Hospice Patients" – **Richmond Area Hospice Agencies** (Heartland Hospice, Odyssey Hospice, Horizon Hospice), 2012
22. Speaker - "Treatment of Patients with Cancer" – **Richmond Area Public Schools: Clover Hill High School, Robious Middle School**, Midlothian, VA, 2013
23. Speaker - "An initial evaluation for low-risk prostate cancer may be incomplete without a multi parametric MRI", **bd**, 2014
24. Speaker - "Prostate MRI: A technology that can help men avoid unnecessary treatment" **Richmond Area Rotary Clubs**, 2014
25. Speaker - "Advances in Lung Cancer Treatment Stereotactic Radiotherapy", **Cancer Action Coalition of Virginia**, Richmond, 2017
26. Speaker - "The Role of Stereotactic Radiotherapy for Early-Stage Lung Cancer", **Lung Cancer Alliance Annual 3rd Annual Screening & Care Conference**, Washington DC, 2017

27. Keynote Speaker - "Curing Lung Cancer Through Early Detection & Multi-Disciplinary Care". **American Lung Association Lung Force Expo**, Richmond, VA, 2018
28. Invited Speaker – "Radiotherapy 101". **Lungevity Foundation International Lung Cancer Survivorship Conference**, Washington DC, 2019
29. Invited Speaker – **ALK Summit Survivorship Conference**, Atlanta, 2019
30. Invited Panelist – "Why Biomarker Testing is Important- Emory Univ", **GO2 Foundation for Lung Cancer - Lung Cancer Living Room™** (Virtual), 2020
31. Invited Speaker – "Radiotherapy 101". **Lungevity Foundation International Lung Cancer Survivorship Conference** (Virtual), 2020
32. Invited Panelist – "Lung Cancer Living Room - Hope, Resilience, and Camaraderie; Voices from Veterans", **GO2 Foundation for Lung Cancer – Lung Cancer Living Room™** (Virtual), 2020
33. Invited Panelist – **ALK Summit Survivorship Conference**, (Virtual), 2021
34. Invited Speaker – "Radiotherapy 101". **Lungevity Foundation International Lung Cancer Survivorship Conference** (Virtual), 2021
35. Invited Speaker – "When Tumors Won't Disappear", **ALKtALK Lecture Series** (Virtual), 2024
36. Invited Speaker – "New Era of Staging and Treatment for Early Stage Lung Cancer", **Northridge Hospital Medical Center**, 2024
37. Invited Speaker – "Screening for Early Lung Cancer by Primary Care Physicians", **JCCC Sponsored Oncology Lecture Series**, February 2025
38. Invited Speaker – "Updated Benefits of Lung Cancer Screening", **Orange County Lung Cancer Screening Learning Collaborative**, April 2025
39. Invited Lecture – "Screening for Early Lung Cancer by Primary Care Physicians", **Charles Drew University Family Practice Residency Program**, February 2025

Media Appearances

1. Interview - Public Broadcasting System (WCVE), 2016
<https://ideastations.org/radio/news/science-matters-va-cooperative-studies-program-seeks-tackle-lung-cancer-head?fbclid=IwAR0VNWXNdIVEERBtv5n-b0W3pBj87xCYi1lKkZHxnCjn-eBoUf0pJXGooUk>
2. Mention - Society of Thoracic Surgery, 2017 <http://www.sts.org/publications/sts-news/washington-scene-grant-will-fund-lung-cancer-screening-programs-va-facilities>
3. Interview - Lung Cancer Alliance, 2018 <https://lungcanceralliance.org/blog/va-pals-improving-lung-cancer-screening-veterans/>
4. Mention - Vanderbilt University Medical Center, 2018
<https://www.vumc.org/radiology/news-announcements/spalluto-lewis-co-lead-va-pals-national-program-evaluation>
5. Interview – Lungevity Foundation, 2018
<https://lungevity.org/for-patients-caregivers/blogs/experts-blog/va%E2%80%99s-commitment-to-helping-veterans-with-lung-cancer>
6. Mention – The American Society of Clinical Oncology Post, 2018
<http://www.ascopost.com/issues/december-25-2018/low-dose-ct-lung-screening/>
7. Mention – Vanderbilt University Medical Center Reporter, 2019
<https://news.vumc.org/2019/01/17/spalluto-lewis-to-lead-va%E2%80%88lung-screening-initiative/>

8. Author – American College of Radiology Bulletin, 2019 <https://www.acr.org/Practice-Management-Quality-Informatics/ACR-Bulletin/Articles/September-2019/No-Patient-Left-Behind>
9. Author – Federal Practitioner, 2019 https://www.fedprac-digital.com/federalpractitioner/2019_cancer_data_trends/MobilePagedReplica.action?pm=2&folio=S26#pg28
10. Mention - Foundation to Advance VA Research and Education, 2020 <https://faver.foundation/featured-research-projects/lung-cancer-screening-to-save-veterans-lives/>
11. Interview – VAntage Blog, 2020 <https://www.blogs.va.gov/VAntage/80915/partnership-funded-lung-cancer-screening-saved-one-veterans-life/>
12. Interview – VA Office of Research and Development, 2020 <https://www.research.va.gov/currents/0720-VA-works-to-raise-awareness-for-lung-cancer-screening-in-Veterans.cfm>
13. Mention – GO2 Foundation for Lung Cancer, 2020 <https://go2foundation.org/blog/improving-lung-cancer-screening-for-our-veterans-an-update/>
14. Interview – Medical Association of Georgia (Podcast), 2020 <https://www.facebook.com/watch/?v=524584192117279>
15. Interview – The Research Evangelist (Podcast), 2021 <https://researchevangelist.com/podcast/episode-23-dr-drew-moghanaki-dave-bjork-research-evangelist-2021>
16. Author – “Veterans Health Administration’s Lung Precision Oncology Program Helps Individualize Treatment”, IASLC Lung Cancer Newsletter, 2021 <https://www.iaslc.org/iaslc-news/ilcn/veterans-health-administrations-lung-precision-oncology-program-helps-individualize>
17. Mention – “Veterans lung cancer treatment study is largest ever”, UCLA Health, 2022 <https://connect.uclahealth.org/2022/05/09/veterans-lung-cancer-treatment-study-is-largest-ever/>
18. Interview – “Veteran Lung Cancer Risk | Understanding Exposures and Screening Protocols”, Patient Empowerment Network, 2024 <https://powerfulpatients.org/2024/04/25/veteran-lung-cancer-risk-understanding-exposures-and-screening-protocols/>
19. Interview – “Lung Cancer Care for Veterans: Advancements in Radiation Oncology”, Patient Empowerment Network, 2024 <https://powerfulpatients.org/2024/04/25/lung-cancer-care-for-veterans-advancements-in-radiation-oncology/>
20. Interview – “Are There Lung Cancer Outcome Disparities for Veterans?”, Patient Empowerment Network, 2024 <https://powerfulpatients.org/2024/04/25/are-there-lung-cancer-outcome-disparities-for-veterans/>
21. Interview – “Combating Disparities: Veterans’ Healthcare Access and Quality”, Patient Empowerment Network, 2024 <https://powerfulpatients.org/2024/04/25/combating-disparities-veterans-healthcare-access-and-quality/>
22. Interview – “Insights into Veteran Healthcare | Perspectives from VA and Civilian Systems”, Patient Empowerment Network, 2024 <https://powerfulpatients.org/2024/04/25/insights-into-veteran-healthcare-perspectives-from-va-and-civilian-systems/>
23. Interview – “Do Black and Latinx Veterans Face Unique Lung Cancer Challenges?”, Patient Empowerment Network, 2024 <https://powerfulpatients.org/2024/04/25/do-black-and-latinx-veterans-face-unique-lung-cancer-challenges/>

24. Interview – “Lung Cancer Strategies for Veterans: Research and Care Insights”, Patient Empowerment Network, 2024 <https://powerfulpatients.org/2024/04/25/lung-cancer-strategies-for-veterans-research-and-care-insights/>
25. Interview – “How Can Advanced Lung Cancer Be Explained to Newly Diagnosed Veterans?”, Patient Empowerment Network, 2024 <https://powerfulpatients.org/2024/04/25/how-can-advanced-lung-cancer-be-explained-to-newly-diagnosed-veterans/>
26. Interview – “Advancements in Lung Cancer Clinical Trials | Updates for Veterans”, Patient Empowerment Network, 2024 <https://powerfulpatients.org/2024/04/25/advancements-in-lung-cancer-clinical-trials-updates-for-veterans/>
27. Interview – “Swimming with Sharks | Featuring Drs. Neha Vapiwala and Drew Moghanaki”, At The Beam (Podcast), 2024 <https://podcasts.apple.com/us/podcast/s3e1-swimming-w-sharks-feat-drs-neha-vapiwala-drew/id1635578239?i=1000673583160>
28. Interview – “Dr. Drew Moghanaki”, The American Lung Cancer Screening Initiative (Podcast), 2024 <https://podcasts.apple.com/us/podcast/alcsi-podcast-dr-drew-moghanaki/id1774372501?i=1000675999670>
29. Interview – “Reducing the Burden of Radiation”, AACR Cancer Today Magazine, 2024 <https://www.cancertodaymag.org/winter-2024-2025/reducing-radiation-burden/>
30. Interview – “Survivorship Needs for Veterans With Early Lung Cancer”, Medscape 2025, <https://reference.medscape.com/viewarticle/early-lung-cancer-survivorship-veterans-healthcare-support-2025a10002qx>
31. Interview – “America’s Deadliest Cancer Has Abysmal Screening Rates”, NY Times, 2025 <https://www.nytimes.com/2025/11/19/well/lung-cancer-screening-study.html>
32. Interview - “Half of Patients With Advanced Lung Cancer Don’t Get Treatment, Study Finds”, NY Times, 2026 <https://www.nytimes.com/2026/05/07/well/metastatic-lung-cancer-study.html>

PUBLICATIONS / BIBLIOGRAPHY

Research Papers – Peer-Reviewed

1. Cardiff RD, **Moghanaki D**, Jensen RA. Genetically engineered mouse models of mammary intraepithelial neoplasia. *J Mammary Gland Biol Neoplasia*. 2000 Oct;5(4):421-37. Review <https://doi.org/10.1023/a:1009534129331>
2. Maglione JE, Moghanaki D, Young LJ, Manner CK, Ellies LG, Joseph SO, Nicholson B, Cardiff RD, MacLeod CL. Transgenic Polyoma middle-T mice model premalignant mammary disease. *Cancer Res*. 2001 Nov 15;61(22):8298-305 <https://pubmed.ncbi.nlm.nih.gov/11719463/>
3. Maglione JE, McGoldrick ET, Young LJ, Namba R, Gregg JP, Liu L, **Moghanaki D**, Ellies LG, Borowsky AD, Cardiff RD, MacLeod CL. Polyomavirus middle T-induced mammary intraepithelial neoplasia outgrowths: single origin, divergent evolution, and multiple outcomes. *Mol Cancer Ther*. 2004 Aug;3(8):941-53 <https://pubmed.ncbi.nlm.nih.gov/15299077/>
4. Dikov MM, Ohm JE, Ray N, Tchekneva EE, Burlison J, **Moghanaki D**, Nadaf S, Carbone DP. Differential roles of vascular endothelial growth factor receptors 1 and 2 in dendritic cell differentiation. *J Immunol*. 2005 Jan 1;174(1):215-22 <https://doi.org/10.4049/jimmunol.174.1.215>

5. **Moghanaki D.** Denis Parsons Burkitt, FRSM, FRCS (Edinburgh): a passion for learning. *J Pediatr Hematol Oncol.* 2008 Oct;30(10):754-7
<https://doi.org/10.1097/mpb.0b013e318180bba8>
6. **Moghanaki D,** Mick R, Furth EE, Sohal D, Salmon PM, Behbahani A, Morgans AK, Miller SM, Giantonio BJ, Whittington RW, Haller DG, Rosato EF, Plastaras JP. Resection status, age and nodal involvement determine survival among patients receiving adjuvant chemoradiotherapy in pancreatic adenocarcinoma. *JOP.* 2011 Sep 9;12(5):438-44 <https://pubmed.ncbi.nlm.nih.gov/21904068/> .
7. Matsuyama RK, Wilson-Genderson M, Kuhn L, **Moghanaki D,** Vachhani H, Paasche-Orlow M. Education level, not health literacy, associated with information needs for patients with cancer. *Patient Educ Couns.* 2011 Dec;85(3):e229-36
<https://doi.org/10.1016/j.pec.2011.03.022>
8. **Moghanaki D,** Koontz BF, Karlin JD, Wan W, Mukhopadhyay N, Hagan MP, Anscher MS. Elective irradiation of pelvic lymph nodes during postprostatectomy salvage radiotherapy. *Cancer.* 2013 Jan 1;119(1):52-60 <https://doi.org/10.1002/cncr.27712>
9. Matsuyama RK, Lyckholm LJ, Molisani A, **Moghanaki D.** The value of an educational video before consultation with a radiation oncologist. *J Cancer Educ.* 2013 Jun;28(2):306-13 <https://doi.org/10.1007/s13187-013-0473-1>
10. Karlin JD, Koontz BF, Freedland SJ, Moul JW, Grob BM, Wan W, Hagan MP, Anscher MS, **Moghanaki D.** Identifying appropriate patients for early salvage radiotherapy after prostatectomy. *J Urol.* 2013 Oct;190(4):1410-5
<https://doi.org/10.1016/j.juro.2013.04.078>
11. **Moghanaki D,** Cheuk AV, Fosmire H, Anscher MS, Lutz ST, Hagan MP, Dawson GA; U.S. Veterans Healthcare Administration National Palliative Radiotherapy Taskforce. Availability of single-fraction palliative radiotherapy for cancer patients receiving end-of-life care within the Veterans Healthcare Administration. *J Palliat Med.* 2014 Nov;17(11):1221-5 <https://doi.org/10.1089/jpm.2014.0041>
12. Schuster JM, Smith TJ, Coyne PJ, Lutz S, Anscher MS, **Moghanaki D.** Clinic offering affordable radiation therapy to increase access to care for patients enrolled in hospice. *J Oncol Pract.* 2014 Nov;10(6):e390-5
<https://doi.org/10.1200/jop.2014.001505>
13. Serrano N, Chang M, Leland Rogers C, Orton M, Mannino R, Grob M, Agarwal R, **Moghanaki D.** Patient autonomy and shared decision making in the management of urethral cancer. *Pract Radiat Oncol.* 2016 Jan-Feb;6(1):66-70
<https://doi.org/10.1016/j.prro.2015.09.002>
14. **Moghanaki D,** Urdaneta AI, Karlin JD, Koontz BF, Anscher MS. Management of Postprostatectomy Biochemical Relapse With Salvage Radiotherapy: Results of an International Survey. *Am J Clin Oncol.* 2016 Feb;39(1):64-8
<https://doi.org/10.1097/coc.000000000000020>
15. Serrano N, **Moghanaki D,** Asher D, Karlin J, Schutzer M, Chang M, Hagan MP. Comparative study of late rectal toxicity in prostate cancer patients treated with low-dose-rate brachytherapy: With or without supplemental external beam radiotherapy. *Brachytherapy.* 2016 Jul-Aug;15(4):435-441
<https://doi.org/10.1016/j.brachy.2016.04.002>
16. Williams CD, Salama JK, **Moghanaki D,** Karas TZ, Kelley MJ. Impact of Race on Treatment and Survival among U.S. Veterans with Early-Stage Lung Cancer. *J Thorac Oncol.* 2016 Oct;11(10):1672-81 <https://doi.org/10.1016/j.jtho.2016.05.030>
17. Tendulkar RD, Agrawal S, Gao T, Efsthathiou JA, Pisansky TM, Michalski JM, Koontz BF, Hamstra DA, Feng FY, Liauw SL, Abramowitz MC, Pollack A, Anscher MS, **Moghanaki D,** Den RB, Stephans KL, Zietman AL, Lee WR, Kattan MW, Stephenson AJ. Contemporary Update of a Multi-Institutional Predictive Nomogram

- for Salvage Radiotherapy After Radical Prostatectomy. *J Clin Oncol*. 2016 Oct 20;34(30):3648-3654 <https://doi.org/10.1200/jco.2016.67.9647>
18. Pisansky TM, Agrawal S, Hamstra DA, Koontz BF, Liauw SL, Efstathiou JA, Michalski JM, Feng FY, Abramowitz MC, Pollack A, Anscher MS, **Moghanaki D**, Den RB, Stephans KL, Zietman AL, Lee WR, Kattan MW, Stephenson AJ, Tendulkar RD. Salvage Radiation Therapy Dose Response for Biochemical Failure of Prostate Cancer After Prostatectomy-A Multi-Institutional Observational Study. *Int J Radiat Oncol Biol Phys*. 2016 Dec 1;96(5):1046-1053 <https://doi.org/10.1016/j.ijrobp.2016.08.043>
 19. Anscher MS, Chang MG, **Moghanaki D**, Rosu M, Mikkelsen RB, Holdford D, Skinner V, Grob BM, Sanyal A, Wang A, Mukhopadhyay ND. Lovastatin may reduce the risk of erectile dysfunction following radiation therapy for prostate cancer. *Acta Oncol*. 2016 Dec;55(12):1500-1502 <https://doi.org/10.1080/0284186x.2016.1223882>
 20. Golden SE, Thomas CR Jr, **Moghanaki D**, Slatore CG; Early Stage Lung Cancer Comparative Effectiveness Research Consortium. Dumping the information bucket: A qualitative study of clinicians caring for patients with early stage non-small cell lung cancer. *Patient Educ Couns*. 2017 May;100(5):861-870 <https://doi.org/10.1016/j.pec.2016.12.023>
 21. Lewis SL, Porceddu S, Nakamura N, Palma DA, Lo SS, Hoskin P, **Moghanaki D**, Chmura SJ, Salama JK. Definitive Stereotactic Body Radiotherapy (SBRT) for Extracranial Oligometastases: An International Survey of >1000 Radiation Oncologists. *Am J Clin Oncol*. 2017 Aug;40(4):418-422 <https://doi.org/10.1097/coc.000000000000169>
 22. Chang MG, Mukhopadhyay N, Holdford D, Skinner V, Saraiya S, **Moghanaki D**, Anscher MS. Phase 1/2 study of hypofractionated intensity-modulated radiation therapy for prostate cancer including simultaneously integrated boost. *Pract Radiat Oncol*. 2018 May - Jun;8(3):e149-e157 <https://doi.org/10.1016/j.prro.2017.09.007>
 23. Cornwell LD, Echeverria AE, Samuelian J, Mayor J, Casal RF, Bakaeen FG, Omer S, Preventza O, Mai W, Chen G, Simpson KH, **Moghanaki D**, Zhu AW. Video-assisted thoracoscopic lobectomy is associated with greater recurrence-free survival than stereotactic body radiotherapy for clinical stage I lung cancer. *J Thorac Cardiovasc Surg*. 2018 Jan;155(1):395-402 <https://doi.org/10.1016/j.jtcvs.2017.07.065>
 24. Lammers A, Mitin T, **Moghanaki D**, Thomas CR Jr, Timmerman R, Golden SE, Thakurta S, Dziadziuszko R, Slatore CG. Lung cancer specialists' opinions on treatment for stage I non-small cell lung cancer: A multidisciplinary survey. *Adv Radiat Oncol*. 2018 Jan 31;3(2):125-129 <https://doi.org/10.1016/j.adro.2018.01.001>
 25. Gutt R, Malhotra S, Jolly S, **Moghanaki D**, Cheuk AV, Fosmire H, Kelly M, Hoffman-Hogg L, Lutz S, Anscher M, Dawson G; Veterans Health Administration Palliative Radiotherapy Task Force. Management of metastatic spinal cord compression among Veterans Health Administration radiation oncologists. *Ann Palliat Med*. 2018 Apr;7(2):234-241 <https://doi.org/10.21037/apm.2018.03.08>
 26. Nugent SM, Golden SE, Thomas CR Jr, Deffebach ME, Sukumar MS, Schipper PH, Tieu BH, **Moghanaki D**, Wisnivesky J, Slatore C. Patient-clinician communication among patients with stage I lung cancer. *Support Care Cancer*. 2018 May;26(5):1625-1633 <https://doi.org/10.1007/s00520-017-3992-1>
 27. Hwang WL, Tendulkar RD, Niemierko A, Agrawal S, Stephans KL, Spratt DE, Hearn JW, Koontz BF, Lee WR, Michalski JM, Pisansky TM, Liauw SL, Abramowitz MC, Pollack A, **Moghanaki D**, Anscher MS, Den RB, Zietman AL, Stephenson AJ, Efstathiou JA. Comparison Between Adjuvant and Early-Salvage Postprostatectomy

- Radiotherapy for Prostate Cancer With Adverse Pathological Features. *JAMA Oncol.* 2018 May 10;4(5):e175230 <https://doi.org/10.1001/jamaoncol.2017.5230>
28. Anscher MS, Chang MG, **Moghanaki D**, Rosu M, Mikkelsen RB, Holdford D, Skinner V, Grob BM, Sanyal A, Wang A, Mukhopadhyay ND. A Phase II Study to Prevent Radiation-induced Rectal Injury With Lovastatin. *Am J Clin Oncol.* 2018 Jun;41(6):544-548 <https://doi.org/10.1097/coc.0000000000000320>
 29. Ramey SJ, Agrawal S, Abramowitz MC, **Moghanaki D**, Pisansky TM, Efstathiou JA, Michalski JM, Spratt DE, Hearn JWD, Koontz BF, Liauw SL, Pollack A, Anscher MS, Den RB, Stephans KL, Zietman AL, Lee WR, Stephenson AJ, Tendulkar RD. Multi-institutional Evaluation of Elective Nodal Irradiation and/or Androgen Deprivation Therapy with Postprostatectomy Salvage Radiotherapy for Prostate Cancer. *Eur Urol.* 2018 Jul;74(1):99-106 <https://doi.org/10.1016/j.eururo.2017.10.009>
 30. Kapoor R, **Moghanaki D**, Rexrode S, Monzon B, Ray M, Hulick PR, Albuquerque K, Rosenthal SA, Palta JR, Hagan MP. Quality Improvements of Veterans Health Administration Radiation Oncology Services Through Partnership for Accreditation With the ACR. *J Am Coll Radiol.* 2018 Dec;15(12):1732-1737 <https://doi.org/10.1016/j.jacr.2018.06.029>
 31. **Moghanaki D**, Howard, L, De Hoedt A, Aronson W, Kane C, Amling C, Cooperberg M, Terris M, Freedland S. Validity of the National Death Index to Ascertain the Date and Cause of Death in Men Having Undergone Prostatectomy for Prostate Cancer. *Prostate Cancer Prostatic Dis* 2019 <https://doi.org/10.1038/s41391-019-0146-1>
 32. Yerramilli D, **Moghanaki D**, Efstathiou JA. Safeguarding Autonomy of Patients With Bladder Cancer. *Int J Radiat Oncol Biol Phys.* 2019 Jan 1;103(1):81-83 <https://doi.org/10.1016/j.ijrobp.2018.07.2019>
 33. Shah T, Kushnir V, Mutha P, Mahjail M, Patel B, Schutzer M, **Moghanaki D**, Smallfield G, Patel M, Zfass A. Neoadjuvant cryotherapy improves dysphagia and may impact remission rates in advanced esophageal cancer. *Endoscopy International* 2019 <http://dx.doi.org/10.1055/a-0957-2798>
 34. Williams M, Harris E, Kipatrick D, Adler R, Wan W, Chang M, Hagan M, **Moghanaki D**. Prostate Radiotherapy Effects on Testosterone Levels: An Empirical Investigation. *J Radiation Oncology* Oct 30, 2019. doi.org/10.1007/s13566-019-00375-1
 35. Kahn J, Dahman B, McLaughlin C, Kapoor P, Kapoor R, Harris E, Sharma M, Schutzer M, **Moghanaki D**. Rectal Spacing, Prostate Coverage, and Peri-Procedural Outcomes Following Hydrogel Spacer Injection During Low Dose Rate Brachytherapy Implantation. *Brachytherapy* 2020 <https://doi.org/10.1016/j.brachy.2019.11.002>
 36. **Moghanaki D**, Slotman B, Swaminath A, Nelms B, Wang B. Assessing the Variability and Quality of Lung Stereotactic Radiotherapy Treatment Plans using a Web-Based Crowdsourcing Platform. *Practical Rad Oncol* 2020 <https://doi.org/10.1016/j.prro.2019.12.004>
 37. Welp A, Abbott S, Samson P, Shi H, Reda D, Cameron D, Cornwell L, Karas T, Harople D, **Moghanaki D**. The Quality of Peer-Reviewed Publications on Surgery for Early Stage Lung Cancer within the Veterans Health Administration – Sem in Thoracic and Cardiovascular Surgery 2020 <https://doi.org/10.1053/j.semtcvs.2020.04.004>
 38. Nugent S, Golden S, Hooker E, Sullivan D, Thomas C, Deffebach M, Sukumar, M, Schipper P, Tieu B, **Moghanaki D**, Wisnivesky J, Samson P, Robinson C, Slatore C. Longitudinal Health-related Quality of Life among Individuals Considering Treatment for Stage I Non-Small Cell Lung Cancer. *Ann Am Thorac Soc* 2020 <https://doi.org/10.1513/annalsats.202001-029oc>

39. Ricco A, Mukhopadhyay N, Deng Xiaoyan, Holdford D, Skinner V, Saraiya S, **Moghanaki D**, Anscher M, Chang M. Moderately Hypofractionated Intensity Modulated Radiation Therapy with Simultaneous Integrated Boost for prostate Cancer: Five-Year toxicity Results from a Prospective Phase I/II Trial. *Front Oncol* 2020, <http://doi.org/10.3389/fonc.2020.01686>
40. Gutt R, Malhotra S, **Moghanaki D**, Cheuk A, Hoffman-Hogg L, Kelly M, Fosmire H, Dawson G. Radiotherapeutic Care of Patients with Stage IV Lung cancer with Throacic Symptoms in the Veterans Health Administration. *Fed Pract* 2020, 37(suppl 2); S38-42 [PMC7497879](https://pubmed.ncbi.nlm.nih.gov/32520848/)
41. Patel S, Goyal S, Liu Y, **Moghanaki D**, Patel P, Hanasoge S, Dhere V, Shelton J, Godette K, Jani A, Hershatter B, Fischer-Valuck B. Analysis of Radiation Facility Volume and Survival in Men With Lymph Node-Positive Prostate Cancer Treated With Radiation and Androgen Deprivation Therapy. *JAMA Netw Open* 2020 Dec 1;3(12) <https://dx.doi.org/10.1001%2Fjamanetworkopen.2020.25143>
42. Henschke CI, Yip R, Shaham D, Zulueta JJ, Aguayo SM, Reeves AP, Jirapatnakul A, Avila R, **Moghanaki D**, Yankelevitz DF; I-ELCAP Investigators. The Regimen of Computed Tomography Screening for Lung Cancer: Lessons Learned Over 25 Years From the International Early Lung Cancer Action Program. *J Thorac Imaging*. 2021 Jan;36(1):6-23. <https://pubmed.ncbi.nlm.nih.gov/32520848/>
43. Rulach R, Ball D, Chua KLM, Dafele M, De Ruyscher D, Franks K, Gomez D, Guckenberger M, Hanna GG, Louie AV, **Moghanaki D**, Palma DA, Peedell C, Salem A, Siva S, Videtic G, Chalmers A, Harrow S. An international expert survey on the indications and practice of radical thoracic re-irradiation for non-small cell lung cancer. *Advances in Radiation Oncology* 2021 <https://doi.org/10.1016/j.adro.2021.100653>
44. Lewis JA, Spalluto LB, Henschke CI, Yankelevitz DF, Aguayo SM, Morales P, Avila R, Audet CM, Prusaczyk B, Lindsell CJ, Callaway-Lane C, Dittus RS, Vogus TJ, Massion PP, Limper HM, Kripalani S, **Moghanaki D**, Roumie CL. Protocol to Evaluate the Implementation of an Enterprise-Wide Initiative to Increase Access to Lung Cancer Screening in the Veterans Health Administration. *Clinical Imaging* 2021 <https://doi.org/10.1016/j.clinimag.2020.11.059>
45. Spalluto LB, Lewis JA, Stollendorf D, Yeh VM, Callaway-Lane C, Wiener RS, Slatore CG, Yankelevitz DF, Henschke CI, Vogus TJ, Massion PP, **Moghanaki D**, Roumie CL. Organizational Readiness for Lung Cancer Screening: A cross-sectional evaluation at a Veterans Affairs Medical Center. *Am Coll Radiol* 2021 <https://doi.org/10.1016/j.jacr.2020.12.010>
46. Yoon S, Suh R, Abtin F, **Moghanaki D**, Genshalt S, Kamrava M, Drakaki A, Liu S, Venkat P, Lee A, Chang A. Outcomes with multi-disciplinary management of central lung tumors treated with percutaneous high-dose-rate brachytherapy. *Radiation Oncology* 2021 <https://doi.org/10.1186/s13014-021-01826-1>
47. Wilke J, Lipson R, Johnson M, Williams C, **Moghanaki D**, Elliott D, Owen D, Alturi N, Jolly S, Chapman C. Use and Outcomes of SBRT for Early Stage NSCLC Without Pathologic Confirmation in the Veterans Health Care Administration. *Adv Radiation Oncology* 2021 <https://doi.org/10.1016/j.adro.2021.100707>
48. McCall NS, Liu Y, Patel SA, Hershatter B, **Moghanaki D**, Godette KD, et al. Influence of Timing between Androgen Deprivation Therapy and External Beam Radiation Therapy in Patients with Localized, High-Risk Prostate Cancer. *Adv Radiat Oncol*. 2021 <https://doi.org/10.1016/j.adro.2021.100803>
49. Syed Y, Stokes W, Khullar O, Sebastian N, Rupji M, Yuan L, Bradley J, Higgins K, Curran W, Ramalingam S, Sancheti M, Fernandez F, **Moghanaki D**. Surgical Outcomes for Early-Stage Non-Small Cell Lung Cancer at Facilities with Stereotactic

- Body Radiation Therapy Programs. CHEST 2021
<https://doi.org/10.1016/j.chest.2021.11.004>
50. Dhare V, Fischer-Valuck B, Goyal S, Liu Y, Morgan T, Ghavidel E, **Moghanaki D**, Hershatter B, Patel P, Jani A, Godette K, Rossie P, Patel S. Patient-reported outcomes after Low-dose-rate versus High-dose-rate brachytherapy boost in combination with external beam radiation for intermediate and high risk prostate cancer. Brachytherapy 2021 <https://doi.org/10.1016/j.brachy.2021.07.005>
 51. Spalluto LB, Lewis JA, Samuels LR, Callaway-Lane C, Matheny ME, Denton J, Robles JA, Dittus RS, Yankelevitz DY, Henschke CI, Massion PP, **Moghanaki D**, Roumie CL. Association of Rurality with Annual Repeat Lung Cancer Screening in the Veterans Health Administration. J Am Coll Radiol 2022
<https://doi.org/10.1016/j.jacr.2021.08.027>
 52. Sankar K, Bryant AK, Strohbehm GW, Zhao L, Elliott D, **Moghanaki D**, Kelley MJ, Ramnath N, Green MD. Real World Outcomes versus Clinical Trial Results of Durvalumab Maintenance in Veterans with Stage III Non-Small Cell Lung Cancer. Cancers. 2022 <https://doi.org/10.3390/cancers1403061>
 53. Stokes WA, Xiong N, Liu Y, Higgins KA, Tian S, Bradley JD, **Moghanaki D**, Rusthoven CG. Association of Operability With Post-Treatment Mortality in Early-Stage Non-Small Cell Lung Cancer. Clin Lung Cancer. 2022
<https://doi.org/10.1016/j.clcc.2021.12.012>
 54. Donovan JL, Jepson M, Rooshenas L, Paramasivan S, Mills N, Elliott D, Wade J, Reda D, Blazeby JM, **Moghanaki D**, Hwang ES, Davies L. Development of a new adapted QuinteT Recruitment Intervention (QRI-Two) for rapid application to RCTs underway with enrolment shortfalls—to identify previously hidden barriers and improve recruitment, Trials 2022 <https://doi.org/10.1186/s13063-022-06187-y>
 55. Chao HH, Soni PD, Dahman B, Stilianoudakis SC, Ford H, Singh R, Freedland SJ, **Moghanaki D**, Vapiwala N, Chang MG. Comparative Outcomes between Radical Prostatectomy and External Beam Radiation for Patients in the Veterans Health Administration with Gleason 9 and 10 Prostate Cancer, Cancer Medicine 2022
<https://doi.org/10.1002/cam4.4656>
 56. Stokes WA, Behera M, Jian R, Gutman D, Sukhatme V, Lowe M, Ramalingam S, Sikhatme V, **Moghanaki D**. Impact of concomitant fibrates on immunotherapy outcomes for advanced non-small cell lung cancer. Cancer Medicine 2022
<https://doi.org/10.1002/cam4.4847>
 57. Characterizing Twitter Influencers in Radiation Oncology. Valle LF, Chu FI, Smith M, Wang C, Lee P, **Moghanaki D**, Chino FL, Steinberg ML, Raldow AC. Adv Radiat Oncol. 2022 <https://doi.org/10.1016/j.adro.2022.100919>
 58. Lorenz J, **Moghanaki D**, Keshava H, Harpole DH, Bradley JD, Higgins KA, Rusthoven CG Jr, Stokes WA. Lung Cancer. Sins of omission: A meta-research study evaluating the omission of operability in published retrospective comparisons of surgery with stereotactic body radiotherapy in patients with early-stage non-small cell lung cancer. Lung Cancer 2022 <https://doi.org/10.1016/j.lungcan.2022.11.011>
 59. Strayer TE, Spalluto LB, Burns A, Lindsell CJ, Henschke CI, Yankelevitz DF, **Moghanaki D**, Dittus RS, Vogus TJ, Audet C, Kripalani S, Roumie CL, Lewis JA. Using the Framework for Reporting Adaptations and Modifications-Expanded (FRAME) to study adaptations in lung cancer screening delivery in the Veterans Health Administration: A cohort study. Implementation Science Communication 2022
<https://doi.org/10.21203/rs.3.rs-1862731/v1>
 60. Bryant A, Sankar K, Zhao L, Strohbehm G, Elliott D, **Moghanaki D**, Kelley M, Ramnath R. De-escalating adjuvant durvalumab treatment duration in stage III non-small-cell lung cancer Eur J Cancer 2022 <https://doi.org/10.1016/j.ejca.2022.04.033>

61. Sebastian N, Stokes W, Behera M, Jiang R, Gutman D, Giuste F, Burns A, Ramalingam S, Sukhatme V, Lowe M, Ramalingam S, Sukhatme V, **Moghanaki D** The Association of Improved Overall Survival with NSAIDs in Non-Small Cell Lung Cancer Patients Receiving Immune Checkpoint Inhibitors. *Clinical Lung Cancer* 2023 <https://doi.org/10.1016/j.clcc.2022.12.013>
62. Smith C, Xiang M, Yoon S, Lee A, Ruan D, Goldman J, Cummings A, Lisberg A, Garon E, **Moghanaki D**. Brief Report: Severe Pneumonitis Following Combined Thoracic Radiotherapy and Osimertinib. *JTO Clin and Research Reports* 2023 <https://doi.org/10.1016/j.jtocrr.2023.100468>
63. Lewis JA, Bonnet K, Schlundt DG, Byerly S, Lindsell CJ, Henschke CI, Yankelevitz DF, York SJ, Hendler F, Dittus RS, Vogus TJ, Kripalani S, **Moghanaki D**, Audet C, Roumie CL and Spalluto LB. Rural barriers and facilitators of lung cancer screening program implementation in the veterans health administration: a qualitative study. *Front. Health Serv* 2023. <https://doi.org/10.3389/frhs.2023.1209720>
64. Lewis JA, Samuels L, Weems J, Park D, Winter R, Callaway-Lane C, Lindsell C, Slatore C, Wiener R, Dittus R, Yankelevitz D, Henschke CI, Kripalani S, **Moghanaki D**, Matheny M, Vogus T, Roumie C, Spalluto L. The association of organizational readiness with lung cancer screening utilization. *Am J Prev Med* 2023. <https://doi.org/10.1016/j.amepre.2023.05.018>
65. **Moghanaki D**, Karas T, Timmerman R, Cameron R, Ritter T, Shi Hairong, Leiner M, Feng H, Skinner V, Robin L, Odle C, Sindowski T, Snodgrass A, Huang G, Reda D, Harpole D. Protocol for the Veterans Affairs Cooperative Studies Program Study Number 2005: A Phase 3 Randomized Trial of Lung Cancer Surgery or Stereotactic Radiotherapy for Operable Early-Stage Non-Small Cell Lung Cancer. *CHEST Pulmonary* 2024 <https://doi.org/10.1016/j.chpulm.2023.100024>
66. Z Wang, V Li, F Chu, V Yu, A Lee, D Low, **D Moghanaki**, P Lee, X S Qi. Predicting Overall Survival for Patients with Malignant Mesothelioma Following Radiotherapy via Interpretable Machine Learning. *Cancers* 2023 <https://doi.org/10.3390/cancers15153916>
67. Edwards DM, Sankar K, Alseri A, Jiang R, Schipper M, Miller S, Dess K, Strohhahn GW, Elliott DA, Moghanaki D, Ramnath N, Green MD, Bryant AK Pneumonitis After Chemoradiotherapy and Adjuvant Durvalumab in Stage III Non-Small Cell Lung Cancer. *IJROBP* 2024 <https://doi.org/10.1016/j.ijrobp.2023.09.050>
68. **Moghanaki D**, Taylor J, Bryant AK, Vitzthum LK, Sebastian N, Gutman D, Burns A, Huang Z, Lewis JA, Spalluto LB, Williams CD, Sullivan DR, Slatore CG, Behera M, Stokes WA. Lung Cancer Survival Trends in the Veterans Health Administration. *Clin Lung Cancer* 2024 <https://doi.org/10.1016/j.clcc.2024.02.009>
69. Ritter TA, Timmerman RD, Hanfi HI, Shi H, Leiner MK, Feng H, Skinner VL, Robin LM, Odle C, Amador G, Sindowski T, Snodgrass AJ, Huang GD, Reda DJ, Slatore C, Sears CR, Cornwell LD, Karas TZ, Harpole DH, Palta J, **Moghanaki D**. Centralized Quality Assurance for Stereotactic Body Radiation Therapy Treatments Delivered in the Veterans Affairs Cooperative Studies Program Study #2005: A Phase III Randomized Trial of Lung Cancer Surgery or Stereotactic Radiotherapy for Operable Early-Stage Non-Small Cell Lung Cancer (VALOR). *Practical Rad Onc* 2024 <https://doi.org/10.1016/j.prro.2024.07.010>
70. Sebastian NT, Stokes WA, Behera M, Jiang R, Gutman DA, Huang Z, Burns A, Sukhatme V, Lowe MC, Ramalingam SS, Sukhatme VP, **Moghanaki D**. The association of azole antifungals with overall survival in patients with non-small cell lung cancer receiving immune checkpoint inhibitors. *Oncologist*. 2024 <https://doi.org/10.1093/oncolo/oyae262>

71. LaVigne AW, Doss VL, Berizzi D, Johnston FM, Kiess AP, Kirtane KS, **Moghanaki D**, Roumeliotis M, Yang GQ, Viswanathan AN. The History and Future of Multidisciplinary Cancer Care. *Semin Radiat Oncol* 2024 <https://doi.org/10.1016/j.semradonc.2024.07.006>
72. Nikitas J, Yanagawa J, Sacks S, Hui EK, Lee A, Deng J, Abtin F, Suh R, Lee JM, Toste P, Burt BM, Revels SL, Cameron RB, **Moghanaki D**. Pathophysiology and Management of Chest Wall Pain after Surgical and Non-Surgical Local Therapies for Lung Cancer. *JTO Clin Res Rep* 2024 <https://doi.org/10.1016/j.jtocrr.2024.100690>
73. Wu TC, Lee A, Suh R, Oughourlian TC, Abtin F, Hagio MA, Park SJ, Chang AJ, **Moghanaki D**. Salvage percutaneous high-dose-rate brachyablation after stereotactic body radiation therapy for early-stage non-small cell lung cancer. *J Contemp Brachytherapy* 2024 <https://doi.org/10.5114/jcb.2024.139103>
74. Boyle, P., Naumann, L., Lauria, M., Miller, C., Andosca, R., Savjani, R., O'Connell, D., **Moghanaki, D.**, Barjaktarevic, I., Goldin, J., & Low, D. A. Introducing a novel sub-millimeter lung CT image registration error quantitation tool. *Medical Physics* 2024 <https://doi.org/10.1002/mp.17552>
75. Lauria M, Kim M, O'Connell D, Lao Y, Miller C, Nauman L, Boyle P, Raldow A, Lee A, Savjani R, **Moghanaki D**, Low D. A Retrospective Analysis of the First Clinical 5DCT Workflow. *Cancers* 2025. <https://doi.org/10.3390/cancers17030531>
76. Lewis JA, Stranick A, Pennings J, Samuels LR, Byerly S, Helton J, Park D, Winter R, Matheny ME, Henschke CI, Yankelevitz DF, Hendler F, York SJ, Callaway-Lane C, Tindle HA, Dittus RS, **Moghanaki D**, Spalluto LB, Roumie CR. National Survey of Lung Cancer Screening Eligibility in United States Veterans. *American Journal of Preventive Medicine* 2025. <https://doi.org/10.1016/j.amepre.2025.01.015>
77. Spalluto LB, Bonnet K, Schlundt D, Audet CM, Henschke CI, Yankelevitz DF, York SJ, MD, Hendler F, Dittus, RS, **Moghanaki D**, Roumie CL, Lewis JA. A Qualitative Evaluation of Factors Influencing the Lung Cancer Screening Program. *J Gen Int Med* 2025 <https://doi.org/10.1007/s11606-025-09714-0>
78. Tupper H, Mendelson D, Doo F, Carlos R, Bialecki B, Prosper A, **Moghanaki D**, Servais E, Flores E, Cummings A. Imaging Interoperability: #DitchtheDisk is a Health Equity Imperative for Lung Cancer Screening & Beyond. *Ann Thor Surg*, accepted July 19, 2025 <https://doi.org/10.1016/j.athoracsur.2025.07.001>
79. Lewis JA, Samuels LR, Spalluto LB, Lindsell C, Henschke CI, Yankelevitz DF, Callaway-Lane C, Dittus RS, Tindle HA, Wiener RS, Slatore CG, **Moghanaki D**, Audet CM, Roumie CL. Provider Determinants and Preferences for Lung Cancer Screening Implementation: A Brief Report. Accepted to *JTO Clinical and Research Reports* September 11, 2025. <https://doi.org/10.1016/j.jtocrr.2025.100905>
80. Lin Y, Ding R, **Moghanaki D**, Aberle DR, Hsu W, Prosper AE. Opportunities for Predicting Lung Cancer Screening Nonadherence: A Systematic Review and Meta-Analysis. *Journal of the American College of Radiology*. 2025;22. <https://doi.org/10.1016/j.jacr.2025.08.053>
81. Heiden BT, Eaton DB Jr, Palta J, Chang SH, Yan Y, Baumann AA, Thomas TS, Schoen MW, Tohmasi S, Rossetti N, Patel MR, Kreisel D, Nava RG, Meyers BF, Kozower BD, Puri V, **Moghanaki D**. Availability of multidisciplinary treatment modalities and outcomes among patients with resected early-stage non-small cell lung cancer. *JNCI Cancer Spectrum*. 2025. <https://doi.org/10.1093/jncics/pkaf104>
82. Lewis JA, Samuels LR, Spalluto LB, Lindsell C, Henschke CI, Yankelevitz DF, Callaway-Lane C, Dittus RS, Tindle HA, Wiener RS, Slatore CG, **Moghanaki D**, Audet CM, Roumie CL. Provider behavioral determinants and preferences for lung cancer screening implementation: a brief report. *JTO Clinical and Research Reports*. 2025. <https://doi.org/10.1016/j.jtocrr.2025.100905>

83. **Moghanaki D**, Videtic G, Singh AK, Siva S, Gage DL, Lee A, Deng J, Xiang M. "Fifteen-Year National Trends in Single-Fraction Stereotactic Body Radiation Therapy Utilization for Stage I Non-Small Cell Lung Cancer", *JCO Onc Prac* 2026, <https://doi.org/10.1200/OP-25-00826>
84. Sakowitz S, Tupper HI, Benjamin LN, Oh S, He T, Ronaghi R, Channick CL, Rosenberg BJ, Salehi-Rad R, Smith MI, Bando JM, Young TJ, Barjaktarvic I, Velez Velez MA, Gower A, Cummings AL, Goldman J, Lisberg AE, Garon EB, Yanagawa J, Cameron EA, Burt BM, Revels SL, Toste P, Lee JM, Lee A, Deng J, Lee H, Benharash P, **Moghanaki D**. Stereotactic Body Radiation Therapy Utilization Trends for Stage I Non-Small Cell Lung Cancer. *Chest* 2026. <https://doi.org/10.1016/j.chest.2025.10.040>
85. Castagna-McLeod C, Brooks H, Bonnet K, Audet C, Terry MS, Tindle HA, Schlundt D, York S, Hendler F, **Moghanaki D**, Dittus R, Roumie C, Lewis JA, Spalluto LB. "It's a Donut - Veteran Perspectives of Lung Cancer Screening with Low-Dose Computed Tomography". *Patient Educ Couns* 2026, <https://doi.org/10.1016/j.pec.2026.109571>
86. Giraud N, van Rossum PSN, Ebrahimi S, Palacios MA, **Moghanaki D**, Schneiders FL, Senan S. "Efficacy and safety of adrenalectomy and stereotactic ablative radiotherapy (SABR) for adrenal metastases: A systematic review and meta-analysis". *Radioth & Oncol* 2026, <https://doi.org/10.1016/j.radonc.2026.111599>
87. Bullard AJ, Tupper HI, Su K, Gu L, Valle LF, Garraway IP, Washington DL, Bird CE, Winn RA, Freedland SJ, Williams CD, **Moghanaki D**. Equity and Cancer Survival Among Veterans Health Administration Patients: A Systematic Review and Meta-Analysis. *JAMA Net Open* 2026 <https://doi.org/10.1001/jamanetworkopen.2026.21585>
88. Charters JA, Ghafarian M, Abdulkadir Y, Luximon DC, Neylon J, **Moghanaki D**, Kishan A, Steinberg M, Lamb JM. Automated Assessment of Nondosimetric Aspects of Prostate Radiation Therapy Treatment Quality in a Large Plan Database, *Adv Radioth Onc* 2026, <https://doi.org/10.1016/j.adro.2026.102048>

Editorials, Commentaries, and Letters to the Editor

1. **Moghanaki D**, Anscher MS. Prostate cancer: should men with metastases undergo radical prostatectomy? *Nat Rev Urol*. 2013 <https://doi.org/10.1038/nrurol.2013.154>
2. **Moghanaki D**, Freedland SJ, Anscher M. Re: Comparison of mortality outcomes after radical prostatectomy versus radiotherapy in patients with localized prostate cancer: a population-based analysis. *Int J Urol*. 2013 <https://doi.org/10.1111/j.1442-2042.2012.03212.x>
3. **Moghanaki D**, Karas T. Surgery versus SABR for NSCLC. *Lancet Oncol*. 2013 [https://doi.org/10.1016/s1470-2045\(13\)70445-5](https://doi.org/10.1016/s1470-2045(13)70445-5)
4. Vapiwala N, **Moghanaki D**, Movsas B. Cultivating Tomorrow's Clinician Scientists: We Reap What We Sow. *Int J Radiat Oncol Biol Phys*. 2015 <https://doi.org/10.1016/j.ijrobp.2014.12.038>
5. Vapiwala N, **Moghanaki D**, Movsas B. In Reply to Mell. *Int J Radiat Oncol Biol Phys*. 2015 <https://doi.org/10.1016/j.ijrobp.2015.05.046>
6. **Moghanaki D**, Timmerman RD, Slatore CG, Niewoehner DE, Karas TZ. In Regard to Valle et al. *Int J Radiat Oncol Biol Phys*. 2016 <https://doi.org/10.1016/j.ijrobp.2016.05.031>
7. A. Lammers, S. Golden, C.R. Thomas, T. Mitin, **D. Moghanaki**, R.D. Timmerman, C. Slatore, Lung Cancer Specialists' Opinions on Treatments for Stage I Lung Cancer:

- A Multidisciplinary Survey, *Int J Radiation Onc Biol Physics*. 2016
<https://doi.org/10.1016/j.ijrobp.2016.06.43>
8. **Moghanaki D**, Simone CB 2nd, Rimmer A, Karas TZ, Donington J, Shirvani SM, Daly M, Videtic GM, Movsas B; ASTRO Evidence-Based Guideline Committee for Stereotactic Body Radiation Therapy (SBRT) for Early-Stage Non–Small Cell Lung Cancer. The value of collaboration between thoracic surgeons and radiation oncologists while awaiting evidence in operable stage I non-small cell lung cancer. *J Thorac Cardiovasc Surg*. 2018 <https://doi.org/10.1016/j.jtcvs.2017.09.001>
 9. Cornwell LD, **Moghanaki D**. Collaborating to assess the role of stereotactic body radiation therapy in medically operable stage I non-small cell lung cancer. *J Thorac Diseases*. 2018 <https://doi.org/10.21037/jtd.2018.08.83>
 10. **Moghanaki D**, Hagan M. Strategic Initiatives for Veterans with Lung Cancer. *Fed Practitioner*. 2020 <https://doi.org/10.12788/fp.0019>
 11. Swaminath A, Ritter T, Louie AV, Palma DA, Guckenberger M, Senan S, Bezjak A, **Moghanaki D**. Performing SBRT in the Fly-With-Caution Zone: Are We Heeding the Advice of Daedalus? *Int J Radiat Oncol Biol Phys*. 2022
<https://doi.org/10.1016/j.ijrobp.2021.10.143>
 12. **Moghanaki D**, Lisberg A, Oh S, Lee J. Unresectable Stage III NSCLC Should Not be Treated with Neoadjuvant Therapy and Re-Evaluated for Resection. *J Thoracic Oncology*. 2023 <https://doi.org/10.1016/j.jtho.2023.06.005>
 13. Senan S, Schneiders F, **Moghanaki D**. Sub-lobar resections for peripheral non-small cell lung cancer measuring ≤ 2 cm: Insights from recent clinical trials. *Radiother Oncol*. 2024 <https://doi.org/10.1016/j.radonc.2024.110094>
 14. **Moghanaki D**, Keshava H, Das, M. Evolution of Combination Therapies for Clinical Stage IIIA Non–Small Cell Lung Cancer. *ASCO Daily News*, April 2023
<https://dailynews.ascopubs.org/doi/evolution-combination-therapies-clinical-stage-iiia-non-small-cell-lung-cancer>
 15. Wu J, Thomas T, Tavalire HF, Vecchio F, Kyriakides TC, Crothers K, Kelley MJ, **Moghanaki D**, Shofer S, Hendler F, Feldman L. Letter to the Editor in Response to "Adherence to Annual Lung Cancer Screening in a Centralized Academic Program". *Clin Lung Cancer*. 2024 <https://doi.org/10.1016/j.clc.2024.08.009>
 16. **Moghanaki D**, Eala M, Feldman J, DiJulio T, Gorayski P. Lung cancer: A One-Way Ticket. *JNCI Spectrum*, 2024 <https://doi.org/10.1093/jncics/pkae098>
 17. Huertas A, **Moghanaki D**, Siva S. Comment on Wu et al's article on toxicity in patients receiving radiotherapy for ultracentral stage I non-small cell lung cancer. *Radiother Oncol*, 2025 <https://doi.org/10.1016/j.radonc.2025.110805>
 18. **Moghanaki D**, Cameron E, Garon E. Unbridled enthusiasm for neoadjuvant chemoimmunotherapy followed by surgery for locally advanced non-small cell lung cancer. *Lung Cancer* 2025 <https://doi.org/10.1016/j.lungcan.2025.108628>
 19. **Moghanaki D**, Prosper AE, Aberle DR. Misleading concerns about computed tomography scans. *JNCI Cancer Spectrum*. 2025.
<https://doi.org/10.1093/jncics/pkaf090>
 20. **Moghanaki D**, Yom SS, Vapiwala N. "Missing the target: radiation, "toxicity," and public fear", *International Journal of Radiation Oncology, Biology, Physics*. 2025.
<https://doi.org/10.1016/j.ijrobp.2025.08.003>
 21. Studts JL, Carter-Bawa L, Feldman J, Schiller JH, Scharnetzki E, Pantelas J, Manley E Jr, Williamson TJ, Rivera MP, Sakoda LC, Wood D, Kazerooni EA, Rosenthal LS, Smith RA, **Moghanaki D**. Embracing compassion for people facing lung cancer: the American Cancer Society National Lung Cancer Roundtable. *Annals of Internal Medicine*. 2025. <https://doi.org/10.7326/ANNALS-24-0316>

22. Carter-Bawa L, Williamson TJ, Alvey N, Begnaud A, Boatman D, Brown DP, Cook D, Donaldson D, Feldman J, Hamann HA, Kazerooni E, Kearney L, Manley E, **Moghanaki D**, Ostroff JS, Pantelas J, Park ER, Rigney M, Rosenthal L, Scharnetzki E, Shiller J, Smith RA, Stangl AL, Warner ET, Wood DE, Studts JL. Confronting nihilism and stigma in lung cancer: The nurse practitioner's role in restoring hope and trust. *J of Am Ass of Nurse Practitioners*, 2025
<https://doi.org/10.1097/JXX.0000000000001230>
23. Tupper HI, Shrager JB, **Moghanaki D**, Simone CB II, Kazerooni EA, Hart EM, Cooke DT, Velotta JB, Tong BC, Keshava HB, Erkmen CP, Yang CFJ, Servais EL. Misinformation and overestimation of computed tomography lung cancer screening harms—methodology matters: a joint statement from the Society of Thoracic Surgeons, the American Society for Radiation Oncology, and the American College of Radiology. *Annals of Thoracic Surgery*. 2025;
<https://doi.org/10.1016/j.athoracsur.2025.11.005>
24. Tupper HI, Shrager JB, **Moghanaki D**, Simone CB II, Kazerooni EA, Hart EM, Cooke DT, Velotta JB, Tong BC, Keshava HB, Erkmen CP, Yang CFJ, Servais EL. Misinformation and overestimation of computed tomography lung cancer screening harms—methodology matters: a joint statement from the Society of Thoracic Surgeons, the American Society for Radiation Oncology, and the American College of Radiology. *International Journal of Radiation Oncology, Biology, Physics*. 2025;
<https://doi.org/10.1016/j.ijrobp.2025.12.030>
25. Tupper HI, Shrager JB, **Moghanaki D**, Simone CB II, Kazerooni EA, Hart EM, Cooke DT, Velotta JB, Tong BC, Keshava HB, Erkmen CP, Yang CFJ, Servais EL. Misinformation and overestimation of computed tomography lung cancer screening harms—methodology matters: a joint statement from the Society of Thoracic Surgeons, the American Society for Radiation Oncology, and the American College of Radiology. *Journal of the American College of Radiology*. 2025;
<https://doi.org/10.1016/j.jacr.2025.12.023>
26. **Moghanaki D**, Gower A. "Safety First", *IJROBP* 2026,
<https://10.1016/j.ijrobp.2025.12.009>

Review Articles

1. Weiss J, **Moghanaki D**, Plastaras JP, Haller DG. Improved patient and regimen selection in locally advanced rectal cancer: who, how, and what next? *Clin Colorectal Cancer*. 2009 Oct;8(4):194-9 <https://doi.org/10.3816/cc.2009.n.033>
2. Schutzer ME, Orio PF, Biagioli MC, Asher DA, Lomas H, **Moghanaki D**. A review of rectal toxicity following permanent low dose-rate prostate brachytherapy and the potential value of biodegradable rectal spacers. *Prostate Cancer Prostatic Dis*. 2015 Jun;18(2):96-103 <https://doi.org/10.1038/pcan.2015.4>
3. **Moghanaki D**, Chang JY. Is surgery still the optimal treatment for stage I non-small cell lung cancer? *Transl Lung Cancer Res*. 2016 Apr;5(2):183-9
<https://doi.org/10.21037/tlcr.2016.04.05>
4. Berman AT, Rosenthal SA, **Moghanaki D**, Woodhouse KD, Movsas B, Vapiwala N. Focusing on the "Person" in Personalized Medicine: The Future of Patient-Centered Care in Radiation Oncology. *J Am Coll Radiol*. 2016 Dec;13(12 Pt B):1571-1578
<https://doi.org/10.1016/j.jacr.2016.09.012>
5. **Moghanaki D**, Turkbey B, Vapiwala N, Ehdaie B, Frank SJ, McLaughlin PW, Harisinghani M. Advances in Prostate Cancer Magnetic Resonance Imaging and Positron Emission Tomography-Computed Tomography for Staging and

- Radiotherapy Treatment Planning. *Semin Radiat Oncol*. 2017 Jan;27(1):21-33
<https://doi.org/10.1016/j.semradonc.2016.08.008>
6. Videtic GMM, Donington J, Giuliani M, Heinzerling J, Karas TZ, Kelsey CR, Lally BE, Latzka K, Lo SS, **Moghanaki D**, Movsas B, Rimner A, Roach M, Rodrigues G, Shirvani SM, Simone CB 2nd, Timmerman R, Daly ME. Stereotactic body radiation therapy for early-stage non-small cell lung cancer: Executive Summary of an ASTRO Evidence-Based Guideline. *Pract Radiat Oncol*. 2017 Sep - Oct;7(5):295-301
<https://doi.org/10.1016/j.prro.2017.04.014>
 7. Weder W, **Moghanaki D**, Stiles B, Siva S, Rocco G. The great debate flashes: Surgery versus stereotactic body radiotherapy as the primary treatment of early-stage lung cancer. *Eur J Cardiothorac Surg*. 2017 Dec 21
<https://doi.org/10.1093/ejcts/ezx410>
 8. Kothari G, Loblaw A, Tree AC, van As NJ, **Moghanaki D**, Lo SS, Ost P, Siva S. Stereotactic Body Radiotherapy for Primary Prostate Cancer. *Technol Cancer Res Treat*. 2018 Jan 1;17
<https://doi.org/10.1177/1533033818789633>
 9. Kothari G, Ost P, Cheung P, Blanchard P, Tree AC, van As N, Lo S, **Moghanaki D**, Loblaw A, Siva S. Trends in Management of Oligometastatic Hormone-Sensitive Prostate Cancer. *Curr Oncol Rep*. 2019
<https://doi.org/10.1007/s11912-019-0791-5>
 10. Pacheco M, **Moghanaki D**. Local consolidative therapy for oligometastatic patients with stage IV non-small cell lung cancer may improve survival, but unanswered questions remain. *Transl Lung Ca Research* 2020
<https://doi.org/10.21037/tlcr.2019.06.07>
 11. Taylor J, Rusthoven C, **Moghanaki D**, Prophylactic Cranial Irradiation or MRI Surveillance for extensive stage small cell lung cancer. *J Thorac Disease* 2020
<https://doi.org/10.21037/jtd.2020.03.80>
 12. Kumar S, Chmura S, Robinson C, Lin S, Gadgeel S, Donington J, Feliciano J, Stinchcombe T, Werner-Wasik M, Edelman M, **Moghanaki D**. Alternative Multidisciplinary Management Options for Locally Advanced NSCLC During the Coronavirus Disease 2019 Global Pandemic. *J Thoracic Oncology* 2020
<https://doi.org/10.1016/j.jtho.2020.04.016>
 13. Ocanto A, Torres L, Linde M, Rincón D, Fernández Pascual C, Sevilla B, Gonsalves B, Teja M, Guijarro M, Glaría L, Hernanz R, Zafra-Martin J, Sanmamed N, Kishan A, Alongi F, **Moghanaki D**, Nagar H, Couñago F. MR-LINAC, a new partner in Radiation Oncology: current landscape. *Cancers* 2024
<https://doi.org/10.3390/cancers16020270>
 14. Senan S, Schneiders F, **Moghanaki D**. Sub-lobar resections for peripheral non-small cell lung cancer measuring ≤ 2 cm: Insights from recent clinical trials. *Radiother Oncol* 2024. <https://10.1016/j.radonc.2024.110094>
 15. Bruycker A, Schneiders F, Gulstene S, **Moghanaki D**, Louie A, Palma D, Senan S. Evaluation of Chest CT-Scans Following Lung Stereotactic Ablative Radiotherapy: Challenges and New Insights. *Lung Cancer* 2024,
<https://doi.org/10.1016/j.lungcan.2024.107848>
 16. Carter-Bawa L, Williamson TJ, Alvey N, Begnaud A, Boatman D, Brown DP, Cook D, Donaldson D, Feldman J, Hamann HA, Kazerooni E, Kearney L, Manley E, **Moghanaki D**, Ostroff JS, Pantelas J, Park ER, Rigney M, Rosenthal L, Scharnetzki E, Shiller J, Smith R, Stangl AL, Warner ET, Wood DE, Studts JL. (2025). Confronting Nihilism and Stigma in Lung Cancer: The Nurse Practitioner's navig in Restoring Hope and Trust. *Journal of the American Association of Nurse Practitioners* 2026, <https://10.1097/JXX.0000000000001230>

Chapters

1. **D. Moghanaki**, T. Smith. Chapter 15: When should radiopharmaceuticals be considered for pain management? in Goldstein & Morrison: Evidence-Based Practice of Palliative Medicine. Eds. N Goldstein, R.S. Morrison, Elsevier, 2011
2. **D. Moghanaki**, T. Smith. Chapter 14: When should radiotherapy be considered for pain management? What principles should guide the consideration of limited fraction versus full dose radiotherapy? in Goldstein & Morrison: Evidence-Based Practice of Palliative Medicine. Eds. N Goldstein, R.S. Morrison, Elsevier, 2011
3. **D. Moghanaki**, Chapter 68: Cancer of the Penis and Male Urethra, in Perez & Brady's Principles and Practice of Radiation Oncology, Eds. E. Halperin, L. Brady, C. Perez, D. Wazer, Wolters Kluwer, Updating Author, 2012
4. **D. Moghanaki**, Chapter 67: Testicular Cancer, in Perez & Brady's Principles and Practice of Radiation Oncology, Eds. E. Halperin, L. Brady, C. Perez, D. Wazer, Wolters Kluwer, Updating Author, 2012
5. **D. Moghanaki**, Chapter 66: Intermediate & High Risk Prostate Cancer, in Perez & Brady's Principles and Practice of Radiation Oncology, Eds. E. Halperin, L. Brady, C. Perez, D. Wazer, Wolters Kluwer, Updating Author, 2012
6. **D. Moghanaki**, Chapter 65: Low Risk Prostate Cancer, in Perez & Brady's Principles and Practice of Radiation Oncology, Eds. E. Halperin, L. Brady, C. Perez, D. Wazer, Wolters Kluwer, Updating Author, 2012
7. **D. Moghanaki**, Chapter 64: Bladder Cancer, in Perez & Brady's Principles and Practice of Radiation Oncology, Eds. E. Halperin, L. Brady, C. Perez, D. Wazer, Wolters Kluwer, Updating Author, 2012
D. Moghanaki, Chapter 63: Cancers of the Kidney, Renal Pelvis, and Ureter, in Perez & Brady's Principles and Practice of Radiation Oncology, Eds. E. Halperin, L. Brady, C. Perez, D. Wazer, Wolters Kluwer, Updating Author, 2012
8. **D. Moghanaki**, T. Karas. Section VI. Considerations Specific to Surgical or Procedural Trials, Section E: Patient Recruitment and Retention in Procedural Trials, in Clinical Trials Design in Invasive Operative and Non-Operative Procedures, Eds. K. Itani & D. Reda, Springer Science, 2017, <https://doi.org/10.1007/978-3-319-53877-8>
9. **D. Moghanaki**, C. Bravo Iniguez, M. Jaklitsch. Lung Cancer in Older Adults: Local Treatment, in Geriatric Oncology, Ed. M. Extermann, Springer 2018, https://doi.org/10.1007/978-3-319-57415-8_32
10. **D. Moghanaki**, S. Saraiya, J. Salama., General Principles of Radiation Oncology, in Modern Thoracic Oncology, Eds. R. Cameron, D. Gage, O. Olevsky, World Scientific
11. J. Taylor, W. Stokes, **D. Moghanaki**, Never Ending Story: Surgery versus SBRT in Early-Stage NSCLC, in Advances in Radiation Oncology in Lung Cancer, Third Edition, Ed. B. Jeremic, Springer 2023, <https://doi.org/10.1007/978-3-031-34847-1>
12. Qian D, Stokes W, Siddiqi A, **Moghanaki D**. Never-Ending Story: Surgery Versus SBRT in Early-Stage NSCLC. In: Jeremić B, ed. Advances in Radiation Oncology in Lung Cancer. 3rd ed. Springer; 2023. <https://link.springer.com/book/10.1007/978-3-031-34847-1>

Abstract Presentations

1. **D. Moghanaki***. Transport of Acetylcholine into Presynaptic Vesicles by Vesicular Acetylcholine Transporter: A Structure-Function Analysis. (**Poster**) Texas Medical Association Annual Meeting, Austin, TX, 1998

2. C. Manner*, E. Hsu, S. Joseph, **D. Moghanaki**, J. Maglione, B. Nicholson, M. Frilot, J. Kleeman, and C.L. MacLeod. The Roles of iNOS and CAT2 in Breast Cancer Growth and Metastasis. (**Poster**). Modeling Human Mammary Cancer in Mice Conference, Jackson Laboratory, Bar Harbor, Maine, 1999
3. **D. Moghanaki***. L-arginine-Nitric Oxide Modulation of Tumor Growth and Metastasis in Bigenic Transgene Knockout Mammary Tumor Mice. (**Oral Presentation**). 12th Annual Texas Tech University Health Sciences Center Student Research Day, Lubbock, TX, 1999
4. B. Nicholson*, C. K Manner, E. Hsu, S. Joseph, J. Maglione, **D. Moghanaki**, J. Kleeman, R.D. Cardiff, and C.L MacLeod. Genetic Analysis of Arginine Transport and Nitric Oxide in Breast Cancer Growth and Metastasis. (Poster). American Association for Cancer Research, 91st Annual Meeting, San Francisco, 2000
5. **D. Moghanaki***. High-level nitric oxide modulation of tumor growth and metastasis by the inducible transport of arginine. (**Oral Presentation**). Howard Hughes Medical Institute 2000 Meeting of Medical Student Fellows. Chevy Chase, MD, 2000
6. M. Dikov*, **D. Moghanaki**, J. Ohm, S. Nadaf, D. Carbone. VEGFR-1 is a Primary Mediator of VEGF Inhibitory Effect on Dendritic Cell Differentiation. (**Poster**). American Association for Cancer Research, 93rd Annual Meeting, San Francisco, 2002
7. **D. Moghanaki***, P. Salmon, R. Mick, A. Bebehani, A. Morgans, E. Furth, D. G. Haller, W. Sun, J. M. Metz, R. Whittington, E. F. Rosato Retrospective Review of Pts Treated with Adjuvant Chemoradiation Following Resection of Pancreatic Adenocarcinoma. (**Poster**) Abstract #147 ASCO-GI Symposium 2008, Orlando
8. J. Haynes, **D. Moghanaki**, A. Morgans, P. Salmon, E. Furth, B. Giantonio, J. Drebin, E. Rosato, R. Whittington, J. Metz. Survival following partial pancreatectomy and radiation for ampullary adenocarcinoma. (**Proceedings**) ASCO Annual Meeting, [J Clin Oncol 26: 2008 (May 20 suppl; abstr 15614)]
9. P. Salmon, **D. Moghanaki**, R. Mick, E. Furth, A. Behbehani, A. Morgans, J. Drebin, E. Rosato, R. Whittington, B. Giantonio. Number and percentage of pathologically involved lymph nodes in patients with pancreatic adenocarcinoma predicts for overall survival (OS) in pts treated with postoperative adjuvant chemoradiotherapy. (**Proceedings**) ASCO Annual Meeting, [J Clin Oncol 26: 2008 (May 20 suppl; abstr 15509)]
10. A. Morgans, **D. Moghanaki**, R. Mick, E. Furth, P. Salmon, A. Behbehani, J Drebin, E. Rosato, R. Whittington, B. Giantonio. Survival following resection of pancreatic cancers may not be affected by length of hospital stay or delay to initiating adjuvant chemoradiation. (**Poster**) ASCO Annual Meeting, [J Clin Oncol 26: 2008 (May 20 suppl; abstr 4639)]
11. **D. Moghanaki**, A. Behbehani, A. Morgans, P. Salmon, E. Furth, W. Sun, B. Giantonio, J. Metz, E. Rosato, R. Whittington. Outcomes with postoperative chemoradiation in patients with gross residual disease following surgical resection of pancreatic adenocarcinoma. (**Abstract**) ASCO Annual Meeting, [J Clin Oncol 26: 2008 (May 20 suppl; abstr 15628)]
12. **D. Moghanaki***, B. Koontz, J Karlin, N. Mukhopadhyay, B. Yan, M. Hagan, M. Anscher. Improved Biochemical Complete Response (bCR) and Biochemical Relapse-Free Survival (bRFS) with Whole Pelvis (WPRT) versus Prostate Bed (PBRT) Radiotherapy in Patients Undergoing Salvage Treatment Following Prostatectomy. (**Oral Presentation, Annual Scientific Award**), ASTRO Annual Meeting 2010, San Diego
13. J. Karlin*, B. Koontz, N. Mukhopadhyay, M. Hagan, M. **Anscher, D. Moghanaki**. Exploring the Ideal Therapeutic Window for Successful Post-Prostatectomy Salvage

- Radiotherapy Below a Relapsed PSA of 1.0 ng/mL (**Oral Presentation**) ASTRO Annual Meeting 2011, Miami
14. A. Urdaneta, J. Karlin, M.S. Anscher, **D. Moghanaki**, Current Practice Trends for Managing Post-Prostatectomy Biochemical Relapse with Salvage Radiotherapy: Results of a World-Wide Survey (**Poster**) ASTRO Annual Meeting 2011, Miami
 15. B. Adams*, **D. Moghanaki**, W. Wan, A. Cassano, S. Szentpetery. The United States Department of Veteran Affairs Healthcare System Provides a Suitable Multi Institutional Setting for Phase III Randomized Trials of Stereotactic Ablative Radiotherapy versus Lobectomy in Patients with Medically Operable Stage I Non-Small Cell Lung Cancer (NSCLC), (**Poster**) ASTRO/ASCO Chicago Multidisciplinary Symposium in Thoracic Oncology 2012, San Francisco
 16. M. D. Orton*, E. Weiss, M. G. Chang, **D. Moghanaki**, N. Roman, R. Vera, M. Nedelka, A. Urdaneta, J. Schuster. Contour Variability during Stereotactic Body Radiation Therapy (SBRT) Treatment Planning, and the Effect of Physician Training. (**Poster**) ASTRO Annual Meeting 2012, Boston
 17. B. F. Koontz*, K. Flynn, J. B. Reese, A. I. Urdaneta, **D. Moghanaki**, L. S. Porter. Significant Variation in Provider Discussion of Sexual Side Effects with Radiotherapy Patients. (**Digital Poster**) ASTRO Annual Meeting 2012, Boston
 18. **D. Moghanaki***, B. F. Koontz, J. D. Karlin, W. Wan, N. D. Mukhopadhyay, M. P. Hagan, M. S. Anscher, Elective Pelvic Lymph Node Irradiation, Without Androgen Deprivation Therapy, During Post-Prostatectomy Salvage Radiotherapy (**Digital Poster**) ASTRO Annual Meeting 2012, Boston
 19. J. Schuster*, P. Coyne, S. Lutz, T. Smith, M. Anscher, **D. Moghanaki**. Consultation and Delivery of Palliative Radiotherapy in a Single Day for Cancer Patients Enrolled in Hospice. (**Poster**), American Association of Hospice and Palliative Medicine Annual Assembly, New Orleans; J Pain and Symptom Mgt 2013, 45(2), Pages 451-452, S755
 20. **D. Moghanaki***, H. Fosmire, A. Cheuk, M. Anscher, S. Lutz, G. Dawson. Availability of Single Fraction Palliative Radiotherapy for Cancer Patients Receiving End-of-Life Care within the Veterans Healthcare Administration. (**Poster**) Association of Veterans Affairs Hematology/Oncology Annual Meeting 2013, Atlanta
 21. N. Tennyson*, N. Mukhopadhyay, **D. Moghanaki**, M. Chang, and M. Hagan. Short term androgen deprivation therapy does not cause long term testosterone suppression or increased acute side effects in patients treated with brachytherapy for prostate cancer. (**Poster**) ASTRO Annual Meeting 2013, Atlanta
 22. M. Schutzer*, **D. Moghanaki**, N. Tennyson, J. Yu, M. Anscher. Simultaneous Radiotherapy Boost to Recurrent Tumor Nodules on Multiparametric MRI after Prostatectomy. (**Poster**) ASTRO Annual Meeting 2013, Atlanta
 23. **D. Moghanaki**, A. Cheuk, H. Fosmire, M. Anscher, M. Hagan, S. Lutz, G. Dawson*. Availability of Single Fraction Palliative Radiotherapy for Cancer Patients Receiving End-of-Care within the Veterans Healthcare Administration. (**Oral Presentation**) American Association of Hospice and Palliative Medicine Annual Assembly 2014, San Diego
 24. **D. Moghanaki***, A. Cheuk, H. Fosmire, M. Anscher, M. Hagan, S. Lutz, G. Dawson. Availability of Single Fraction Palliative Radiotherapy for Cancer Patients Receiving End-of-Care within the Veterans Healthcare Administration. (**Oral Presentation**) American Radium Society 2014, St Thomas, USVI
 25. D. Asher*, **D. Moghanaki**, N. Serrano, J. Karlin, M. 201, M. Chang, M. P. Hagan. The Emergence Of New Late Radiation Toxicities Beyond The Traditional 5 Years Of Follow-up After Low-dose Rate Prostate Brachytherapy. (**Poster**) ASTRO Annual Meeting 2014, San Francisco

26. A. Urdaneta*, B. Grob, P. Fatouros, **D. Moghanaki**, J Yu, M. Hagan, Long-term follow- up after MRI-directed regional salvage brachytherapy for locally recurrent adenocarcinoma of the prostate. **(Poster)** ASTRO Annual Meeting 2014, San Francisco
27. G. Dawson*, A. Cheuk, R. Gutt, S. Jolly, M. Hagan, L. Hoffman-Hogg, H. Fosmire, **D. Moghanaki**, S. Lutz, M. Anscher, M. Kelly. The Availability of and Satisfaction with Palliative Care Services Among Veterans Health Administration (VHA)-Based Radiation Oncologists. **(Poster)**. AAHPM/ASCO/ASTRO/MASCC Palliative Care in Oncology Symposium 2014, Boston.
28. J. Schuster*, K. Tam, N. Skoro, J.B. Cassel, **D. Moghanaki**. Influence of Palliative Care Consult on Radiation Therapy delivery within the Last Six Months of Life. **(Poster)** AAHPM/ASCO/ASTRO/MASCC Palliative Care in Oncology Symposium 2014, Boston.
29. **D. Moghanaki***, D. Holden, N. Kalman, R. Agarwal, J. Hubert, R. Khan, H. Lomas, M. Grob, M. Chang, M. Hagan. Impact of Routine Staging Multiparametric 3T-MRI Scans for Men with Gleason's Score 6 Prostate Cancer. **(Poster)** 15th Annual Meeting of the Society of Urologic Oncology 2014, Bethesda
30. N. Kalman, M. Chang, **D. Moghanaki***, Projecting the Lifetime Costs of Multiparametric MRI-Based Active Surveillance in Low Risk Prostate Cancer – A Break Even Analysis. **(Poster)** 15th Annual Meeting of the Society of Urologic Oncology 2014, Bethesda
31. P. Kapur*, J. Ford, **D. Moghanaki**, R. Datsang, M. Chang, M. Hagan, J. Palta, M. Rosu, Is a "Day30 scan" necessary to evaluate activity-based regulatory compliance in permanent interstitial brachytherapy for prostate cancer? **(Oral Presentation)** American Association of Physicists in Medicine 2014, Anaheim
32. A. Cheuk*, R. Gutt, **D. Moghanaki**, M. Hagan, S. Lutz, S. Jolly, H. Fosmire, M. Delly, L. Hoffman-Hogg, M. Anscher, G. Dawson. Radiotherapeutic Care Within the Veterans Health Administration of US Veterans With Metastatic Cancer to the Brain: Part 2 Clinical Treatment Patterns **(Poster)** American Radium Society 2015, Kuai
33. G. Dawson*, S. Jolly, H. Fosmire, S. Lutz, M. Kelly, R. Gutt, M. **Hagan, D. Moghanaki**, L. Hoffman-Hogg, M. Anscher, A. Cheuk. Radiotherapeutic Care Within the Veterans Health Administration of US Veterans With Metastatic Cancer to the Brain: Part 1 Supportive Measures. **(Poster)** American Radium Society 2015, Kuai
34. N. Kalman*, B. Hillner, **D. Moghanaki**. The Cost Consequences of Multiparametric MRI Based Image Surveillance for Gleason's Score 6 Prostate Cancer. **(Poster)**, ASTRO Annual Meeting 2015, San Antonio
35. N.B. Tennyson*, N.D. Mukhopadhyay, **D. Moghanaki**, M.G. Chang, M.P. Hagan, Posttreatment Testosterone Levels Do Not Affect Rates of Biochemical Failure in Men Who Have Undergone Definitive Radiation for Prostate Cancer: Implications for Testosterone Replacement, **(Poster)**, ASTRO Annual Meeting 2015, San Antonio
36. N. Serrano, B. Adams, S. Szentpetery, L. Rogers, M.G. Chang, **D. Moghanaki**, Can Stereotactic Ablative Radiation Therapy (SABR) Improve Patient Selection for Lung Cancer Surgery and Reduce Perioperative Mortality? **(Poster)**, ASTRO Annual Meeting 2015, San Antonio
37. R. Gutt*, S. Malhotra, S. Jolly, **D. Moghanaki**, A. Cheuk, H. Fosmire, M. Kelly, L. Hoffman-Hogg, S. Lutz, M. Anscher, G. Dawson, Management of Metastatic Spinal Cord Compression Among Veterans Health Administration Radiation Oncologists, **(Poster)**, ASTRO Annual Meeting 2015, San Antonio
38. R. Tendulkar*, S. Agrawal, J. Efstathiou, T. Pisansky, J. Michalski, B. Koontz, D. Hamstra, F. Feng, S. Liauw, M. Abramowitz, A. Pollack, M. Anscher, **D. Moghanaki**, R. Den, K. Stephans, M. Kattan, A Stephenson. Contemporary Update of a Multi-

- institutional Predictive Nomogram for Salvage Radiation Therapy After Prostatectomy (**Oral Presentation**), ASTRO Annual Meeting 2015, San Antonio
39. S. Agrawal*, T. Pisansky, D. Hamstra, S. Liauw, B. Koontz, J. Efstathiou, J. Michalski, F. Feng, M. Abramowitz, A. Pollack, M. Anscher, **D. Moghanaki**, R. Den, K. Stephans, M. Kattan, A. Stephenson, R. Tendulkar. Dose Response for Salvage Radiation Therapy After Radical Prostatectomy in Margin Positive Prostate Cancer. (**Oral Presentation**), ASTRO Annual Meeting 2015, San Antonio
 40. R. Gutt, S. Malhotra, S. Jolly, **D. Moghanaki**, A.V. Cheuk, H. Fosmire, M.D. Kelly, L. Hoffman-Hogg, S. Lutz, M.S. Anscher, G.A. Dawson. Management of Metastatic Spinal Cord Compression Among Veterans Health Administration Radiation Oncologists. (**Poster**) ASTRO Annual Meeting 2015, San Antonio
 41. N. Serrano, B. Adams, S. Szentpetery, C.L. Rogers, M. Chang, **D. Moghanaki***. Can Stereotactic Ablative Radiotherapy (SABR) Improve Patient Selection for Lung Cancer Surgery and Reduce Perioperative Mortality? (**Presenter, Oral Presentation**), 16th World Lung Conference on Lung Cancer 2015, Denver
 42. N. Serrano*, **D. Moghanaki**, D. Asher, J. Karlin, M. Schutzer, M. Chang, M. Hagan. Comparative study of late rectal toxicity in veterans undergoing low-dose rate prostate brachytherapy treated with or without supplemental external beam radiotherapy. (**Poster**) ASCO Genitourinary Cancers Symposium 2016, San Francisco
 43. M. Anscher*, M. Chang, **D. Moghanaki**, M. Rosu, R. Mikkelsen, D. Holdford, V. Skinner, B. Grob, A. Sanval, A. Wang, N. Mukhopadhyay. A Phase II Study to Prevent Radiation-Induced Rectal Injury with Lovastatin. (**Poster**) ASCO Genitourinary Cancers Symposium 2016, San Francisco
 44. L. Cornwell*, R. Haywood-Watson, R. Casal, J. Mayor, A. Echeverria, G. Chen, W. Mai, **D. Moghanaki**, S. Omer, O. Preventza, F. Bakaeen, A. Zhu Stereotactic Body Radiotherapy versus Lobectomy in Veterans with Stage-I Non-Small-Cell Lung Cancer (**Oral Presentation**) Association of VA Surgeons Annual Meeting 2016, Virginia Beach
 45. **D. Moghanaki***, E. Harris, A. Urdaneta, M. Williams, P. Kapoor, J. Yu, M. Schutzer, M. Chang, M. Hagan. Multiparametric MRI Guided Salvage Low Dose Rate Brachytherapy for Locally Recurrent Prostate Cancer. (**Oral Presentation**) World Congress of Brachytherapy 2016, San Francisco
 46. J. Kahn*, P. Kapoor, R. Kapoor, E. Harris, M. Sharma, M. Schutzer, **D. Moghanaki**, Dosimetric Consequences and Acute Toxicity Following Perirectal Hydrogel Spacer Injection During Permanent Prostate Brachytherapy, (**Poster**), ASTRO Annual Meeting 2016, Boston
 47. A. Lammers*, S. Golden, C.R. Thomas, T. Mitin, **D. Moghanaki**, R.D. Timmerman, C. Slatore, Lung Cancer Specialists' Opinions on Treatments for Stage I Lung Cancer: A Multidisciplinary Survey, (**Poster**), ASTRO Annual Meeting 2016, Boston
 48. K. Faricy-Anderson*, R. Carwford, S. Lee, S. Blakoski, J. McDermott, V. Chang, G. Oligario, R. Lapsiwala, E. Henry, K. Berlin, J. Cassel, **D. Moghanaki**. Optimization of Palliative Oncology Care Within the VA Healthcare System (**Poster**) Association of VA Hematology/Oncology Annual Meeting 2017, Denver
 49. P. Soni, S. Stilianoudakis, B. Dahman, M. Chang, N. Vapiwala, **D. Moghanaki**. Comparative Effectiveness of Prostatectomy and Radiation Therapy (RT) in Gleason 9-10 Prostate Cancer (**Oral Presentation**), ASTRO Annual Meeting 2018, San Antonio
 50. J. Donovan, L. Davies, **D. Moghanaki**, V. Skinner, S. Hwang, T. Lynch, JM Gierisch, D. Reda, L. Rooshenas (Oral Presentation). Exploring the translation of the UK QRI

- (QuinteT Recruitment Intervention) to improve and optimise recruitment to clinical trials in the US (**Oral Presentation**). Society of Clinical Trials 2019, New Orleans
51. Spalluto LB, Lewis JA, Callaway-Lane C, Stollendorf D, Prusaczyk B, Limper H, Audet CM, Vogus T, Wiener R, Slatore C, Yankelevitz D, Henschke C, Dittus R, Massion PP, Lindsell C, Kripalani S, **Moghanaki D**, Roumie CL. Organizational Readiness for Lung Cancer Screening in a Veterans Affairs Healthcare System. (**Poster**) International Association for the Study of Lung Cancer, World Conference on Lung Cancer 2019, Barcelona, Spain
 52. S. Abbott, C. Slatore, C. Williams, M. Chang, **D. Moghanaki**. Patients with Stage I NSCLC Who Are Not Treated with Either Surgical Resection or Radiation Therapy. American Society of Radiation Oncology Annual Meeting, (**Digital Poster**) September 2019, Chicago
 53. Y. Syed, W. Stokes, O. Khullar, N. Sebastian, M. Rupji, L. Yuan, J. Bradley, K. Higgins, W. Curran, S. Ramalingam, M. Sancheti, F. Fernandez, **D. Moghanaki**. Surgical Outcomes for Early-Stage Non-Small Cell Lung Cancer at Facilities with Stereotactic Body Radiation Therapy Programs. ASCO 2021 Annual Meeting (**Poster Session**)
 54. Sebastian, NT; Stokes, W; Behera, M; Jiang, R; Gutman, D; Giuste, F; Burns, A; Ramalingam, S; Sukhatme, V; Lowe, M; Ramalingam, S; Sukhatme, V; **Moghanaki, D**. Association of Azole Antifungals with Survival in Patients with Non-Small Cell Lung Cancer Receiving Immunotherapy. ASCO 2021 Annual Meeting (**Online Publication**)
 55. Stokes, W; Behera, M; Jiang, R; Gutman, D; Giuste, F; Burns, A; Sebastian, NT; Ramalingam, S; Sukhatme, V; Lowe, M; Ramalingam, S; Sukhatme, V; **Moghanaki, D**. Effect of antibiotic therapy on immunotherapy outcomes for non-small cell lung cancer: Analysis from the Veterans Health Administration Database. ASCO 2021 Annual Meeting (**Poster Discussion**)
 56. Stokes, W; Behera, M; Jiang, R; Gutman, D; Giuste, F; Burns, A; Sebastian, NT; Ramalingam, S; Sukhatme, V; Lowe, M; Ramalingam, S; Sukhatme, V; **Moghanaki, D**. Association of proton pump inhibitors with survival in Veterans with non-small cell lung cancer receiving immunotherapy. ASCO 2021 Annual Meeting (**Online Publication**)
 57. **Moghanaki, D**; Stokes, W; Behera, M; Jiang, R; Gutman, D; Giuste, F; Burns, A; Sebastian, NT; Ramalingam, S; Sukhatme, V; Lowe, M; Ramalingam, S; Sukhatme, V; Association of Concomitant Immune Checkpoint Inhibitors and Nonsteroidal Anti-Inflammatory Medications on Overall Survival in Patients with Non-Small Cell Lung Cancer. ASCO 2021 Annual Meeting (**Poster Session**)
 58. V. Dhere, B. Fischer-Valuck, S. Goyal, Y. Liu, T. Morgan, B. Ghavidel, **D. Moghanaki**, B. Hershatter, P. Patel, A. Jani, K. Godette, P. Rossi, S. Patel. Toxicity Outcomes after Low-Dose-Rate versus High-Dose-Rate Brachytherapy Boost in Combination with External Beam Radiation for Intermediate and High Risk Prostate Cancer. ASTRO 2021 Annual Meeting (**Poster Session**)
 59. S. Yoon, R. Suh, F. Abtin, **D. Moghanaki**, S. Genshaft, M. Kamrava, A. Drakaki, S. Liu, P. Venkat, A. Lee, A. Chang. Outcomes with multi-disciplinary management of central lung tumors treated with percutaneous high-dose-rate brachytherapy. IASLC 2021 (**Poster, Featured**)
 60. Strayer T, Spalluto LB, Burns A, Lindsell C, Henschke CI, Yankelevitz D, **Moghanaki D**, Dittus RS, Vogus T, Audet C, Kripalani S, Roumie CL, Lewis J. "Using the Framework for Reporting Adaptations and Modifications-Expanded (FRAME) to study lung cancer screening adaptations in the Veterans Health Administration."

(Poster) 15th Annual Conference on the Science of Dissemination and Implementation in Health. Washington DC, 2022

61. This list was not updated between 2022-2024

62. Meehan T, Kearney L, R, Gix G, Engle R, Yee J, Codair K, Gilford A, Jalal S, **Moghanaki D**, Wiener D, Kelley M, Wiener R. A Pilot Study of Pulmonologists' Receptivity to Artificial Intelligence Use. (Poster) American Thoracic Society 2025
63. Sakowitz S, Tupper H, Benjamin L, Oh S, He T, Ronaghi R, Channick C, Rosenberg B, Salehi-rad R, Smith M, Bando J, Young T, Barjaktarevic I, Velez V, Gower A, Cummings A, Goldman J, Lisberg A, Garon E, Yanagawa J, Cameron E, Burt B, Revels S, Toste P, Lee J, Lee A, Deng J, Lee H, Benharash P, **Moghanaki D**. Contemporary Stereotactic Body Radiation Therapy Utilization Trends for Stage I Non Small Cell Lung Cancer, AABIP 2025, WCLC 2025 (E-Poster)
64. Nesbit S, Hammons M, Oughourlian T, Goldman J, Garon E, Cummings A, Lisberg A, Velez M, Gower A, Gage D, Lee A, Deng J, **Moghanaki D**. In-Field Progression Rates Following Concurrent Chemoradiotherapy for Stage III Non-Small Cell Lung Cancer: A Systematic Review. ASTRO 2025, WCLC 2025 (Poster)
65. Harpole D, Karas T, Timmerman R, Cameron R, Ritter T, Leiner M, Feng H, Skinner V, Hyoung S, Odle C, Sindowski T, Snodgrass A, Huang G, Carlson K, **Moghanaki D**. Enrollment Update for the CSP #2005 Phase III Veterans Affairs Lung Cancer Surgery or Stereotactic Radiotherapy Study [VALOR]. WCLC 2025 (Poster)
66. **Moghanaki D**, Videtic D, Singh A, Siva S, Gage D, Lee AI, Deng J, Xiang M. Fifteen-Year Trends in Single-Fraction SBRT Utilization for Stage I Non-Small Cell Lung Cancer. ASTRO 2025 (Poster)
67. Low D, Miller C, O'Connell D, Lauria M, Neylon J, Naumann L, Andosca R, Boyle R, Savjani R, Deng J, **Moghanaki D**. Report of 5DCT for 108 Lung Tumor CT Simulations. ASTRO 2025 (Oral Presentation)
68. Nikitas J, Oughourlian T, Kashan C, Misra A, Nesbit S, Phan J, Wang E, Gage D, Lee A, Deng J, Steinberg M, Jahanshahi N, Yokomizo M, Tappuni S, Suh R, Quirk M, Abtin F, **Moghanaki D**. Comparison of Image Guided Thermal Ablation and Stereotactic Body Radiation Therapy for Primary Non-Small Cell Lung Cancer. ASTRO 2025 (Oral Presentation)
69. Brooks H. L., Gallion, A., Audet, C. M., Selove, R., York, S., Hendler, F., **Moghanaki, D.**, Dittus, R., Roumie, C., Lewis, J. A., & Spalluto, L. B. A qualitative evaluation of storytelling narratives designed as a strategy to increase uptake of lung cancer screening for Veterans. Association for Cancer Research (AACR) Annual Meeting, 2026, San Diego, CA. (Poster)
70. Brooks, H. L., Gallion, A., Audet, C. M., Selove, R., York, S., Hendler, F., **Moghanaki, D.**, Dittus, R., Roumie, C., Lewis, J. A., & Spalluto, L. B. A qualitative evaluation of storytelling narratives designed as a strategy to increase uptake of lung cancer screening for Veterans. Vanderbilt Learning Health System Symposium, 2026, Nashville, TN (Poster).
71. Eala M, **Moghanaki D**, Phan J, Wu J, Wang E, Oughourlian T, Mezgueldi Y, Suh R, Abtin F, Lee A, Chang A. Ten-Year Experience with Percutaneous HDR Brachyablation for Primary and Metastatic Lung Tumors. ASTRO 2025 (Poster)

Other Publications

1. **Moghanaki D**. An ER influenced School of Medicine Bone Marrow Drive. (Letter), JAMA; January 6 (MS / JAMA online web-extras), 1999

2. **Moghanaki D.** Review of 'A Randomized Trial of Chemoradiotherapy and Chemotherapy after Resection of Pancreatic Cancer' Oncolink 2004
<https://www.oncolink.upenn.edu/library/article.cfm?c=8&s=41&id=787>
3. **Moghanaki D.** Review of 'Salvage Radiotherapy in Patients with Relapsed and Refractory Hodgkin's Lymphoma: A Retrospective Analysis From the German Hodgkin Lymphoma study Group' Oncolink 2005
<https://www.oncolink.com/library/article.cfm?c=2&s=30&id=834>
4. **Moghanaki D.** Review of 'Salvage Radiotherapy in Patients with Relapsed and Refractory Hodgkin's Lymphoma: A Retrospective Analysis From the German Hodgkin Lymphoma study Group' Oncolink 2006
<https://www.oncolink.com/library/article.cfm?c=2&s=30&id=834>
5. **Moghanaki D.** Review of 'Study of Paclitaxel, Etoposide, and Cisplatin Chemotherapy Combined with Twice-Daily Thoracic Radiotherapy for Patients with Limited Stage Small Cell Lung Cancer: An RTOG 96-09 Phase II Study'. Oncolink 2006
<http://www.oncolink.org/library/article.cfm?c=2&s=34&id=803>
6. **Moghanaki D.** Review of 'Radical Surgery versus Radiotherapy for Adenocarcinoma of the Prostate'. Oncolink 2006
<https://www.oncolink.upenn.edu/library/article.cfm?c=8&s=43&id=829>
7. **Moghanaki D.** Elective irradiation of pelvic lymph nodes during postprostatectomy salvage radiotherapy, "Beyond the Abstract" Uro Today® Nov 12, 2012
8. Stiles B, **Moghanaki D.** "On the Backs of Specialists: LDCT Screening Has Heightened the Importance of Recent Improvements in Surgical and Radiation Techniques" IASLC News 2020 <https://www.iaslc.org/iaslc-news/ilcn/back-specialists-ldct-screening-has-heightened-importance-recent-improvements>

HONORS / AWARDS

1. California Polytechnic State University – Order of Omega Honorary Society, 1991
2. Texas Medical Association – Honorable Mention Medical Student Poster Award, 1999
3. National Institutes of Health – Summer Teacher Research Opportunities for Education Program (Baylor College of Medicine), Fellowship, 1997
4. Texas Medical Association – Physician Oncology Education Program Scholarship, 1997-99
5. Texas Tech University School of Medicine – Summer Research Fellowship for Medical Students, 1998
6. Texas Tech University Health Sciences Center – Scholarship, 1998-99
7. Howard Hughes Medical Institute Medical Research Program – Fellowship, 1999-00
8. Texas Tech University Health Sciences Center – Student Research Day, 1st place: Medical Student Poster Session, 2000
9. Vanderbilt University – Ann H. Light Endowed Scholarship, 2000-02
10. American Society for Radiation Oncology - Annual Meeting Scientific Abstract Award, 2010
11. Keynote Speaker - MIM Software Annual Users Meeting, 2017
12. Keynote Speaker - American Lung Association Lung Force Expo, 2018
13. Keynote Speaker - Philadelphia Roentgen Ray Society –, 2018
14. Keynote Speaker, UK SABR Consortium, England, 2018
15. Keynote Speaker - Australian & New Zealand College of Radiologists Annual Scientific Meeting, 2019
16. Association of Veterans Hematology/Oncology – Trophy of Service Award, 2021

17. Keynote Speaker – 3rd Annual Conquering Veteran Cancer Together, ASCO Annual Meeting, 2022
18. UCLA Health Jonsson Comprehensive Cancer Center – Diana Gordon Jonsson Award for Clinical Excellence, 2022
19. Keynote Speaker – 3rd Global Summit on Thoracic Malignancies, Hawaii, 2024
20. Editors' Spotlight Award! – themednet, 2025